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2. Summary 
Fish of the genus Xiphophorus belong to the oldest animal models in cancer research. The 
oncogene responsible for the generation of spontaneous aggressive melanoma encodes for a 
mutated epidermal growth factor receptor (Egfr) and is called xmrk for Xiphophorus 
melanoma receptor kinase. Xmrk constitutive activation mechanisms and subsequent 
signaling pathways have already been investigated and charaterized but it is still unknown if 
Egfr ligands may also play a role in Xmrk-driven melanoma formation.  
To investigate the potential role of Egfr ligands in Xmrk-driven melanoma, I firstly analyzed 
the evolution of teleost and tetrapod Egfr/Egfr ligand systems. I especially focused on the 
analysis on the medaka fish, a closely related species to Xiphophorus, for which the whole 
genome has been sequenced. I could identify all seven Egfr ligands in medaka and could 
show that the two teleost-specific Egfr copies of medaka display dissimilar expression 
patterns in adult tissues together with differential expression of Egfr ligand subsets, arguing 
for subfunctionalization of receptor functions in this fish. Our phylogenetic and synteny 
analyses supported the hypothesis that only one gene in the chordate ancestor gave rise to the 
diversity of Egfr ligands found in vertebrate genomes today. I also could show that the Egfr 
extracellular subdomains implicated in ligand binding are not evolutionary conserved between 
tetrapods and teleosts, making the use of heterologous ligands in experiments with fish cells 
debatable. 
Despite its well understood and straight-forward process, Xmrk-driven melanomagenesis in 
Xiphophorus is problematic to further investigate in vivo. Our laboratory recently established 
a new melanoma animal model by generating transgenic mitf::xmrk medaka fishes, a 
Xiphophorus closely related species offering many more advantages. These fishes express 
xmrk under the control of the pigment-cell specific Mitf promoter. During my PhD thesis, I 
participated in the molecular analysis of the stably transgenic medaka and could show that the 
Xmrk-induced signaling pathways are similar when comparing Xiphophorus with transgenic 
mitf::xmrk medaka. These data together with additional RNA expression, protein, and 
histology analyses showed that Xmrk expression under the control of a pigment cell-specific 
promoter is sufficient to induce melanoma in the transgenic medaka, which develop very 
stereotyped tumors, including uveal and extracutaneous melanoma, with early onset during 
larval stages. 
To further investigate the potential role of Egfr ligands in Xmrk-driven melanoma, I made use 
of two model systems. One of them was the above mentioned mitf::xmrk medaka, the other 
was an in-vitro cell culture system, where the EGF-inducible Xmrk chimera HERmrk is 
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stably expressed in murine melanocytes. Here I could show that HERmrk activation strongly 
induced expression of amphiregulin (Areg) and heparin-binding EGF-like growth factor 
(Hbegf) in melanocytes. This regulation was dependent on the MAPK and SRC signaling 
pathways. Moreover, upregulation of Adam10 and Adam17, the two major sheddases of Egfr 
ligands, was observed. I also could demonstrate the functionality of the growth factors by in-
vitro analyses. Using the mitf::xmrk medaka model I could also show the upregulation of a 
subset of ligand genes, namely egf, areg, betacellulin (btc) and epigen (epgn) as well as 
upregulation of medaka egfrb in tumors from fish with metastatic melanoma. All these results 
converge to support an Xmrk-induced autocrine Egfr ligand loop. Interestingly, my in-vitro 
experiments with conditioned supernatant from medaka Egf- and Hbegf-producing cells 
revealed that not only Xiphophorus Egfrb, but also the pre-activated Xmrk could be further 
stimulated by the ligands.  
Altogether, I could show with in-vitro and in-vivo experiments that Xmrk is capable of 
inducing a functional autocrine Egfr ligand loop. These data confirm the importance of 
autocrine loops in receptor tyrosine kinase (RTK)-dependent cancer development and show 
the possibility for a constitutively active RTK to strengthen its oncogenic signaling by ligand 
binding. 
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3. Zusammenfassung 
Fische der Gattung Xiphophorus gehören zu den ältesten Tiermodellen für die 
Krebsforschung. Das im Xiphophorus-System für die Melanomentstehung verantwortliche 
Onkogen codiert für eine mutierte Version des epidermalen Wachstumsfaktorrezeptors (Egfr) 
und wird xmrk (für “Xiphophorus melanoma receptor kinase”) genannt. Die konstitutiven 
Aktivierungsmechanismen dieses Rezeptors und die daraus resultierenden aktivierten 
Signalwege sind bereits gut untersucht und charakterisiert. Dennoch war bisher unbekannt, ob 
Egfr-Liganden auch eine Rolle bei der Xmrk-vermittelten Melanomentstehung spielen.  
Um eine potenzielle Rolle dieser Egfr-Liganden im Xmrk-induzierten Melanom zu 
erforschen, habe ich zunächst die Evolution des Egfr/Egfr-Liganden-Systems in Teleostiern  
und Tetrapoden untersucht. Hierfür fokussierte ich mich im besonderen auf den Medaka-
Fisch, der zum einen eine nahe evolutionäre Verwandtschaft zu Xiphophorus aufweist und 
zum anderen – im Gegensatz zu Xiphophorus - ein komplett sequenziertes und gut annotiertes 
Genom besitzt. Ich konnte alle sieben Egfr-Liganden in Medaka identifizieren und konnte 
weiterhin zeigen, dass die zwei Teleost-spezifischen Egfr-Kopien dieses Fisches ein 
unterschiedliches Expressionsmuster in adulten Geweben aufweisen, welches außerdem mit 
unterschiedlicher Egfr-Liganden-Expression einherging. Diese Daten sprechen für eine 
Subfunktionalisierung der Egfr-Funktionen in Medaka. 
Unsere phylogenetischen und Syntenie-Analysen unterstützen die Hypothese, dass nur ein 
einziges Egfr-Liganden-Gen des Chordaten-Vorfahren der genetische Ursprung für die 
zahlreichen Egfr-Liganden-Gene, die in heutigen Vertrebraten zu finden sind, darstellt.  Ich 
konnte weiterhin zeigen, dass die an der Ligandenbindung beteiligten Domänen des Egfr 
nicht zwischen Tetrapoden und Teleostiern konserviert sind. Diese Daten sprechen somit 
gegen die Verwendung heterologer Liganden in Zellkulturexperimenten mit Fischzellen. 
Trotz der gut verstandenen Konsequenzen einer Xmrk-Expression auf die Pigmentzelle lässt 
sich die Xmrk-vermittelte Melanomentstehung in Xiphophorus relativ schwer in vivo 
untersuchen. In unserem Labor wurde daher kürzlich ein neues Tiermodell für Melanome 
entwickelt. Dabei handelt es sich um einen mitf::xmrk-transgenen Medaka. Diese Fische 
exprimieren xmrk unter der Kontrolle des Pigmentzell-spezifischen Mitf-Promoters. Während 
meiner Doktorarbeit trug ich zur molekularen Analyse der stabil transgenen Tiere bei und 
konnte zeigen, dass die Xmrk-vermittelte Signalgebung in mitf::xmrk-Medakas der von 
Xmrk-exprimierenden Xiphophorus-Fischen gleicht.  
Diese Daten, zusammen mit weiteren RNA-Expressions-, Protein- und histologischen 
Analysen, zeigten, dass die Expression von xmrk unter der Kontrolle eines Pigmentzell-
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spezifischen Promoters ausreichend für die Melanomentstehung in Medaka ist. Eine 
Besonderheit dieses Melanommodelles ist die auffallend stereotype Tumorentstehung. Der 
Beginn der Hyperpigmentierung wird bereits in frühen Larvenstadien sichtbar und führt – je 
nach Fischlinie – anschließend zuverlässig zu extrakutanen Pigmentzelltumoren oder 
invasiven bzw. uvealen Melanomen.  
Um eine potenzielle Funktion der Egfr-Liganden für Xmrk-induzierte Melanome zu 
untersuchen, machte ich mir zwei Modellsysteme zunutze. Eines der beiden Modelle war der 
bereits oben erwähnte mitf::xmrk-transgene Medaka, das andere war ein in-vitro-
Zellkultursystem, bei dem die EGF-induzierbare Xmrk-Chimäre HERmrk stabil in murinen 
Melanozyten exprimiert wird. Hier konnte ich zeigen, dass HERmrk-Aktivierung zu einer 
starken Genexpression der EGFR-Liganden Amphiregulin (Areg) und Heparin-binding EGF-
like growth factor (Hbegf) in Melanozyten führte. Diese Regulierung war abhängig von den 
MAPK- und SRC-Signalwegen. Weiterhin wurde eine Induktion von Adam10 und Adam17, 
den zwei bedeutsamsten Proteasen zur Freisetzung von EGFR-Liganden (“Sheddasen”), 
festgestellt. Ich konnte die Funktionalität der so sezernierten Liganden durch in-vitro-
Experimente nachweisen. Anhand des mitf::xmrk Medaka-Modelles konnte ich ebenfalls 
zeigen, dass sowohl mehrere Egfr-Ligandengene, nämlich egf, areg, betacellulin (btc) und 
epigen (epgn), als auch egfrb in Tumoren von Medaka-Fischen mit metastatischen 
Melanomen heraufreguliert wurden. All diese Daten lassen auf einen durch Xmrk induzierten 
autokrinen EGFR-Liganden-Loop schließen. Interessanterweise zeigte sich durch in-vitro-
Experimente mit konditioniertem Überstand von Medaka Egf- und Hbegf-produzierenden 
Zellen, dass nicht nur Xiphophorus Egfrb, sondern auch das bereits aktivierte Xmrk durch 
beide Liganden weiter stimuliert werden konnte.  
Zusammengefasst zeigen meine in-vitro- und in-vivo-Daten, dass Xmrk in der Lage ist, einen 
funktionalen autokrinen Egfr-Liganden-Loop zu induzieren. Dieses Ergebnis unterstreicht die 
Bedeutung autokriner Loops in Rezeptortyrosinkinasen (RTK)-abhängiger Tumorentstehung 
und zeigt auf, dass selbst die onkogene Signalgebung prädimerisierter RTKs durch 
Ligandenbindung verstärkt werden kann.  
4. Introduction  10 
4. Introduction 
The epidermal growth factor receptor (EGFR) that plays central roles in invertebrate and 
vertebrate development and physiology is one of the most investigated members of the family 
of EGF receptors that also comprises three know homologous receptors: ErbB2 (also called 
Neu or HER2), ErbB3 (HER3) and ErbB4 (HER4). EGFR is a transmembrane tyrosine kinase 
receptor that functions normally in a ligand-dependent fashion forming homodimers, but also 
forming heterodimers with its three homologues (see for a review (Jorissen, Walker et al. 
2003)). Recently, the EGFR has emerged as key target of molecular therapy for solid tumors 
since it also plays central roles in proliferation, angiogenesis, invasiveness, decreased 
apoptosis and loss of differentiation processes (see for a review (Takeuchi and Ito 2010)). 
 
4.1. EGFR functions 
Many functions of EGFR during development were revealed using invertebrate model 
organisms like the nematode Caenorhabditis elegans or the fruit fly Drosophila 
melanogaster, where extensive investigations of EGFR allowed its assignment in cardinal 
functions. In C.elegans, EGFR, also called LET-23, was demonstrated to be involved in 
vulval induction, viability, male spicule development, hermaphrodite ovulation and 
differentiation of ventral uterus and posterior ectoderm (Sundaram 2006). In D.melanogaster, 
EGFR or Drosophila Egf receptor (DER) has been assigned 30 distinct functions, among them 
cell fate induction, cell proliferation and cell migration (Shilo 2003). In these two invertebrate 
organisms, EGFR signaling was demonstrated to take place repeatedly with different 
functions during development. 
During vertebrate embryogenesis EGFR and its ligands are expressed and functional 
whenever epithelial-mesenchymal interactions take place. The epithelial-to-mesenchymal 
transition (EMT) is a critical process in embryonic development and is considered to be the 
single most important mechanism regulating organ development in vertebrates (Gurdon 
1992). Most organs are formed from epithelial and mesenchymal tissues and share common 
morphological features during early development (Thesleff, Vaahtokari et al. 1995). 
Moreover, the EMT process is also thought to be an important mechanism for promoting 
cancer invasion and metastasis (see for a review (Barr, Thomson et al. 2008)). 
Knockout of Egfr in mice is lethal, and, depending on the genetic background, abnormalities 
affect skin, lung and gastrointestinal tract development, but also trigger neurodegeneration 
(Miettinen, Berger et al. 1995; Threadgill, Dlugosz et al. 1995; Sibilia, Steinbach et al. 1998). 
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In adult organs, EGFR signaling maintains cellular activities at equilibrium to preserve 
normal structure and function (homeostasis); this is particularly important for the skin.  
In normal epidermis, a strict balance between proliferation of cells in the basal layer and loss 
of terminally differentiated cells from the surface has to be preserved. In humans, EGFR is 
mostly expressed in keratinocytes in the basal layer of the epidermis (Nanney, McKanna et al. 
1984) where it stimulates cell cycle progression through autocrine and paracrine mechanisms 
(Jost, Kari et al. 2000). However, it also regulates programmed cell death in keratinocytes 
(Stoll, Benedict et al. 1998; Jost, Huggett et al. 2001). Most importantly, activation of the 
EGFR also appears to be crucial for regulation of keratinocyte migration (Gibbs, Silva Pinto 
et al. 2000). This is important for proper development and wound healing processes, but also 
can be responsible for metastasis formation in pathological states. Additionally, upregulation 
of EGFR is leading to autocrine growth of melanocytes which are singly situated between 
keratinocytes (Udart, Utikal et al. 2001). 
Few works are documenting the role of the Egfr and the Egf-family ligands within fish 
species. In zebrafish, the Egfr was shown to promote oocyte maturation in vitro (Pang and Ge, 
2002) and to have cardiovascular functions during development (Goishi et al, 2003). The full-
length zebrafish Egfr and Egf have been cloned and their spatio-temporal pattern of 
expression in the ovary were investigated. Recombinant human EGF was tested on zebrafish 
ovarian follicle cells primary cultures and was shown to act as potential paracrine factor from 
the oocyte to regulate the activin/follistatin system in the follicle cells (Wang et al., 2004). 
Using recombinant EGF, betacellulin (BTC) and heparin-binding EGF-like growth factor 
(HB-EGF), it was also demonstrated that the Egf signaling network in the zebrafish ovarian 
follicle was self-regulated by members of the EGF family (Tse at al., 2008). In the goldfish 
Carassius auratus, use of recombinant EGF and TGFA showed that these growth factors may 
play a role in the regulation of ovarian functions (MacDougall and Van Der Kraak, 1998; Pati 
et al., 1996; Kumar Srivastava and Van Der Kraak, 1995). Finally, in the medaka Oryzias 
latipes, Egfr is present during development supporting the hypothesis that Egfr ligands also 
are important during cleavage, gastrulation and early organogenesis (Boomsma et al., 2001).  
 
4.2. Function of EGFR ligands  
To date, there are seven known ligands to bind the EGFR: epidermal growth factor (EGF), 
transforming growth factor-a (TGFA), amphiregulin (AREG), betacellulin (BTC), epiregulin 
(EREG), heparin-binding egf-like growth factor (HBEGF) and epigen (EPGN). 
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Although all EGFR ligands bind the EGFR within the receptor extracellular ligand-binding 
pocket, they are only partly redundant and their biological effects are astonishingly distinct 
(see for a review (Schneider, Werner et al. 2008)). It is somehow surprising that only the 
absence of HBEGF is lethal in mice due to heart and lung malformations (Iwamoto, 
Yamazaki et al. 2003; Jackson, Qiu et al. 2003). Indeed, HBEGF was later demonstrated to be 
involved in heart development and homeostasis (Iwamoto and Mekada 2006). Conversely, 
mice deficient for AREG or EGF (Luetteke, Qiu et al. 1999), for BTC (Jackson, Qiu et al. 
2003), EREG (Mann, Fowler et al. 1993; Lee, Pearsall et al. 2004; Shirasawa, Sugiyama et al. 
2004), TGFA (Luetteke, Qiu et al. 1993) and even triple null mice that lack AREG, EGF and 
TGFA (Luetteke, Qiu et al. 1999) are viable. These observations point out that some, but not 
all, EGFR ligands display functional redundancy. 
To preserve epidermal homeostasis, four EGFR ligands are of special importance to regulate 
keratinocyte proliferation, differentiation and migration, namely EGF, TGFA, AREG and 
HBEGF (see for a review (Hashimoto 2000) and (Schneider, Werner et al. 2008)). 
Overexpression of EGFR ligands in kerationocytes conducts to different phenotypes 
depending on the ligand. For example, overexpression of AREG was shown to be responsible 
for hyperkeratosis/psoriasis-like phenotype (Cook, Brown et al. 2004), whereas increased 
levels of EGF cause hyperproliferation of basal cells and hair follicle developmental arrest 
(Mak and Chan 2003), BTC transgenic animals have a relatively mild skin phenotype with 
delay in hair cycle induction and increased angiogenesis at wound sites (Schneider, Werner et 
al. 2008). In contrast, overexpression of TGFA causes hyperproliferative tumor-prone skin 
(Vassar and Fuchs 1991; Dominey, Wang et al. 1993).  
Epigen, the newest member of the EGFR ligands, is the least investigated EGF-family growth 
factor. One of its functions is the ability to promote growth of epithelial cells (Strachan, 
Murison et al. 2001), and lately, it was reported that EPGN transgenic mice develop enlarged 
sebaceous glands (Dahlhoff, Muller et al. 2009). Altogether, these data demonstrate 
overlapping and specific functions for the seven ligands in order to maintain epidermis 
homeostasis.  
 
4.3. Egfr is conserved throughout evolution 
The epidermal growth factor receptor (Egfr) as key regulator of fundamental functions in 
multicellular organism development is highly conserved, both in vertebrates and 
invertebrates, at least in triploblastic organisms (meaning all superior and intermediate 
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animals from human to worm that arise from a blastula that possesses three primary germ 
layers: ecto-, meso- and endoderm) (Stein and Staros 2006; van Kesteren, Gagatek et al. 
2008). There is to date no evidence for presence of Egfr in simpler diploblastic animals, like 
jellyfish and corals, which arise from a blastula that possesses two primary germ layers: 
ectoderm and endoderm. 
In coelomate organisms, Egfr was isolated in protostomian animals like the nematode worm 
Caenorhabditis elegans (Aroian, Koga et al. 1990), the bivalve mollusc Mytilus 
galloprovincialis (Canesi, Malatesta et al. 2000) and the gastropod mollusc Lymnaea 
stagnalis (van Kesteren, Gagatek et al. 2008). Within the non-chordate deuterostomes, Egfr 
was identified in insects (Lycett, Blass et al. 2001) (Gibson and Tolbert 2006) (Nakamura, 
Mito et al. 2008), including the fruit fly Drosophila melanogaster (Schejter, Segal et al. 
1986). It was also isolated in the echinoderm Paracentrototus lividus (Romancino, Montana 
et al. 2008). In acoelomate organisms, Egfr was also identified in the flatworm Schistosoma 
mansoni (Ramachandran, Skelly et al. 1996). 
Within the Chordata phylum, there is evidence for the presence of Egfr in bony fish, 
amphibians, reptiles, birds and mammals, as their sequenced genomes harbour well-defined 
Egfr encoding DNA (www.ensembl.org) (Hubbard, Aken et al. 2009). Noteworthy, two 
copies for the Egfr can be identified in teleost fish. Indeed, it is now generally accepted that 
an additional whole genome duplication event took place in the evolution of teleost fishes 
approximately 320-350 million years ago that was termed “fish-specific genome duplication 
(FSGD; reviewed in (Postlethwait, Amores et al. 2004; Meyer and Van de Peer 2005)). Most 
teleost gene duplicates, about 80%, encountered pseudogenization or nonfunctionalization 
during evolution, with elimination of one of the duplicated copy (Jaillon, Aury et al. 2004; 
Woods, Wilson et al. 2005). It is believed that gene duplicates have to acquire functional 
divergence to be maintained in the genome during evolution, encountering either 
neofunctionalization, an adaptive process where one copy mutates to acquire a function that 
was not present in the pre-duplication gene (Ohno 1970), either subfunctionalization, a neutral 
process where the two copies partition the ancestral function (Ohno, Wolf et al. 1968; Force, 
Lynch et al. 1999). 
So far, no Egfr has been identified in the Protochordates, Cyclostomes and Chondrichthyes 
(cartilaginous fish). 
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4.4. EGFR structure and mode of activation  
The archetypal human epidermal growth factor receptor (EGFR) was the first member of the 
transmembrane tyrosine kinase receptor family to be discovered (Carpenter, King et al. 1978) 
and sequenced (Downward, Yarden et al. 1984; Ullrich, Coussens et al. 1984). The EGFR and 
its pathways, that govern cell growth and differentiation during embryogenesis and adult 
homeostasis, is to date one of the most extensively investigated signaling systems (Yarden 
and Shilo 2007). The EGFR was also the first cell-surface receptor to be linked to cancer (de 
Larco and Todaro 1978) and its deregulation either by mutation, overexpression, or from 
EGFR stimulation through autocrine loops is involved in many human cancers. 
EGF receptors are anchored in the cell membrane and comprise an extracellular region (~630 
amino acid residues), a single transmembrane domain (~23 residues), an intracellular 
juxtamembrane domain (~40 residues), a tyrosine-kinase domain (~260 residues) and a C-
terminal regulatory region (~232 residues) (Burgess, Cho et al. 2003; Linggi and Carpenter 
2006) (Figure 1A). The extracellular region comprises four subdomains, referred to as I to IV 
(Lax et al. 1998b), or as L1, CR1, L2 and CR2 (Ward, Hoyne et al. 1995). They are involved 
in receptor activation by ligand binding and/or oligodimerization.  
 
Fig. 1: EGFR structure and mode of activation. (A) Overall EGFR structure comprising the 
extracellular, transmembrane, juxtamembrane, tyrosine kinase and C-terminal regulatory domains. 
The extracellular region comprises four subdomains, I to IV, also referred to as large EGF binding 
domain 1 (L1), cysteine-rich domain 1 (CR1), L2 and CR2. (B) Different steps of EGFR activation: 
autoinhibitory tethered monomer, untethered monomer, ligand-stabilized extended, and ligand-
induced activated dimer conformations.  
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Subdomains I and III are homologous to each other and build the ligand-binding pocket, 
while subdomains II and IV are cystine rich and are implicated in receptor dimerization. 
Crystal structure analyses of EGFR ectodomain complexed either with EGF or with TGFA 
(Garrett, McKern et al. 2002; Ogiso, Ishitani et al. 2002) revealed the molecular mechanisms 
by which the extracellular region of the EGFR (sEGFR) shifts from a dimerization-inhibited 
conformation, called the tethered conformation, to a ligand-binding induced dimerization-
competent conformation, called the extended conformation (Figure 1B). In the tethered 
conformation, the dimerization arm on subdomain II is buried by intramolecular interactions 
with subdomain IV (Ferguson, Berger et al. 2003). Binding of ligand within the ligand-
binding pocket shaped by subdomains I and III allows subdomain rearrangement, thereby 
exposing the subdomain II dimerization arm which is necessary for EGFR dimerization. 
Recently, additional crystallographic approaches and biochemical studies from other regions 
of native and mutated forms of the EGFR revealed that the cytoplasmic juxtamembrane 
domain also plays a major role in receptor dimerization, and consequently may also be 
involved in the allosteric control of ligand binding (Jura, Endres et al. 2009; Red Brewer, 
Choi et al. 2009). In any case, EGFR dimerization upon ligand binding is thought to 
reposition the two cytoplasmic tyrosine kinase domains in order to allow efficient trans-
phosphorylation of tyrosine residues in the kinase activation loop, the juxtamembrane region 
and the cytoplasmic domain (see for a review (Hubbard 2004)). 
 
4.5. EGFR signaling 
Activation of the EGF receptor by binding of extra-cellular proteins from the EGF-family of 
growth factors induces receptor dimerization. Subsequent phosphorylation of the cytoplasmic 
C-terminal part of the EGFR by autophosphorylation or by transphospshorylation (by 
collagen domain protein Src or Jak-2 kinases) on tyrosine residues is providing docking sites 
for the Src homology 2 (SH2) or phospho-tyrosine binding (PTB) domains of intracellular 
signal transducers and adaptors proteins (Schlessinger, 2000; Yarden and Sliwkowski, 2001; 
Holbro and Hynes, 2004; Citri and Yarden, 2006). Due to the diversity of molecules that 
complex or are phosphorylated by the EGFR, multiple signaling pathways can be 
simultaneously activated, the four major highly conserved signaling pathways being the Ras-
mitogen-activated protein kinase (MAPK) cascade (Schlessinger, 2000), the phosphoinositide 
3-kinase (PI3K)/Akt pathway (Cantlay, 2002; Davis, 2000), the Signal Transducer and 
Activator of Transcription (STAT) transcription factors (Silva, 2004) and the Src pathway. 
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The Shc, Grb2 and Ras/MAPK pathway  
MAPKs cascades downstream of cell surface EGFRs are involved in the regulation of cell 
proliferation and survival processes. Following EGFR tyrosine kinase activation kinase by 
auto- or by transphosphorylation, the complex formed by the adaptor proteins Grb2 and Sos 
binds directly or via association with the adaptor molecule Shc to specific sites on the 
receptor (Sasaoka, Langlois et al. 1994). Relocation of the Grb2/Sos complex to the EGFR at 
the plasma membrane facilitates the interaction of membrane-associated Ras with Sos, with 
exchange of Ras-bound GDP for GTP and hence in Ras activation. Activated Ras activates in 
turn serine/threonine kinase Raf-1 (Hallberg, Rayter et al. 1994). Activated Raf-1 initiates 
phosphorylation, activation and nuclear translocation of Erk-1 and Erk-2. Activated Erk can 
translocate to the nucleus where they phosphorylate and regulate various nuclear transcription 
factors (e.g., Elk1, Ets2) ultimately leading to change in gene expression (Johnson and 
Vaillancourt 1994; Schulze, Nicke et al. 2004). Activated MAPK also acts as inhibitor in a 
negative feedback loop for this pathway by dissociation of the Grb2-Sos complex induced by 
MAPK phosphorylation of Sos (Langlois, Sasaoka et al. 1995). 
Another major pathway activated upon ligand binding to the EGFR is the PI3-K/Akt pathway, 
involved in cellular processes including proliferation, survival, adhesion and migration (for a 
review see (Cantley 2002)). The association occurs between the SH2 domain of the PI3-K 
p85 subunit and phosphorylated C-terminal part of the EGFR. It has to be mentioned that in 
humans ErbB3 and not EGFR is the major binding partner of the PI3-K (Kim, Sierke et al. 
1994; Ram and Ethier 1996). Once phosphorylated, PI3-K generates the second messenger 
phosphatidylinositol-3,4,5-triphosphate (PIP3), for which best characterized target is the 
Ser/Thr kinase Akt (PKB). Akt binds in turn to the lipid and is translocated to the plasma 
membrane where it is phosphorylated and activated by phosphoinositide-dependent-kinase-1 
(PDK-1) (see for a review (Nicholson and Anderson 2002)).  
Signal transducers and activators of transcription (STAT) proteins are transcription factors 
involved in cellular proliferation, differentiation, apoptosis and oncogenesis. They interact 
with phosphotyrosine residues of the Egfr via their Src homology 2 domains, dimerize and 
translocate from the cytoplasm to the nucleus where they bind regulatory elements in the 
promoter of target genes to regulate their transcription (Yu and Jove 2004).  
SRC kinase (short for sarcoma) is a member of the family of nonreceptor tyrosine kinase that 
plays a critical role in the regulation of cell proliferation, migration, adhesion, as well as  in 
angiogenesis and immune function (Yeatman 2004). Via activation of a series of substrates, 
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including focal adhesion kinase, PI3K and STAT proteins, SRC can function independently in 
the cytosol or cooperate with receptor tyrosine kinase signaling, serving as signal transducer 
and enhancer of Egfr activation (Jorissen, Walker et al. 2003). 
 
4.6. Phylogenetic distribution of EGFR ligands  
In mammals such as humans, EGFR has to date seven known ligands that all are peptide 
growth factors: EGF, TGFA, AREG only bind EGFR, whereas BTC, EREG, HBEGF and 
EPGN bind both EGFR and ErbB4 (Harris, Chung et al. 2003; Schneider and Wolf 2009). It 
is likely that no other EGFR ligands exist since an in-depth genome-wide search with 
algorithms based on genomic and cDNA structures did not reveal further potential EGFR 
ligands (Kochupurakkal, Harari et al. 2005). 
The seven Egfr ligands characterized in humans are also present in all sequenced vertebrate 
genomes. Reptiles, chicken, zebra finch and also the amphibian Xenopus tropicalis display all 
seven Egfr ligands sequences in their genome. In teleost fish, all seven Egfr ligands were 
identified among the seven species investigated but no single teleost fish was found to 
harbour all seven Egfr ligands at once (Stein and Staros 2006).  
However, among invertebrates, only one Egfr ligand was found in the protostomian 
C.elegans, namely Lin-3 (Hill and Sternberg 1992), while four Egfr ligands were 
characterized in the deuterostomian arthropod D.melanogaster: Gurken, Spitz, Vein and 
Keren (Freeman 1998) (Stein and Staros 2006).  
 
4.7. Structure of Egfr ligands 
Egfr ligands are type I transmembrane proteins which, with the exception of Egf - comprise 
an N-terminal region, an Egf domain (or Egf motif), a short juxtamembrane extension, a 
hydrophobic transmembrane domain and a cytoplasmic C-terminal tail (Figure 2A). Egf 
features a unique structure in mammals, with eight extracellular Egf motifs in addition to the 
Egfr interacting Egf domain located close to the cell membrane. 
The seven Egfr ligands have a relatively low overall protein sequence homology of about 
25%, but the stretch of 43 amino acids building the Egf motif with its six conserved cysteines 
is exhibiting high protein sequence homology (Harris, Chung et al. 2003). The six cysteine 
residues C1 to C6 are building three disulfide bridges between C1 and C3, C2 and C4, and C5 
and C6, called the A, B and C loops, respectively (Figure 2B).  
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Noteworthy, AREG and HB-EGF are the only ligands to possess an additional N-terminal 
hydrophilic heparin-binding site, thus conveying binding to heparan sulfate proteoglycans 
(HSPGs) on the cell surface and within the extracellular matrix. Binding of growth factors to 
heparin sulfate (HS) chains have been demonstrated to modulate the cellular response to 
growth factors (Forsten-Williams, Chu et al. 2008). HB-EGF also serves as diphtheria toxin 
receptor, allowing the toxin to enter the cell via binding to and endocytosis with proHB-EGF 
(Mitamura, Higashiyama et al. 1995).  
In mammals, the mature, soluble forms of EGFR ligands have to be released from the initially 
synthesized membrane-bound precursors to interact with the EGFR. 
 
 
Fig. 2: EGFR ligands. (A) The seven EGFR ligand transmembrane precursors: epidermal growth 
factor (EGF), transforming growth factor alpha (TGFA), amphiregulin (AREG), betacellulin (BTC), 
epiregulin (EPI), heparin-binding EGF-like growth factor (HBEGF) and epigen (EPGN). (B) Overall 
structure of a mature EGFR ligand with the 6 conserved cysteines building the three disulfide bounds 
C1-C3, C2-C4 and C5-C6 that generate the A, B and C loops.  
 
4.8. Activation of EGFR ligands by ADAM family members. 
One of the most important post-translational regulation events rendering Egfr ligands 
available is the proteolytic cleavage of an extracellular fragment of the ligand precursor in 
order to release the EGF motif. Egfr ligands precursors are released from the cell membrane 
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by specific sheddases called ADAMs (A Disintegrin And Metalloproteases) (Sahin, Weskamp 
et al. 2004; Sahin and Blobel 2007).  
ADAMs are membrane-anchored proteins of about 750 amino acids length that belong to the 
matrix metalloproteinase family. They are responsible for ectodomain shedding of cell surface 
proteins such as growth factors, cytokines, cell adhesion molecules, and receptors. Therefore 
they are involved in a number of physiological processes. Up to now, there are at least 40 
ADAMs known in various species, from filamentous fungi, yeast (Saccharomyces pombe), 
invertebrates (Caenorhabditis elegans, Drosophila melanogaster) (Pan and Rubin 1997; 
Huang, Huang et al. 2003; Nakamura, Abe et al. 2004), to vertebrates (hamsters, mice and 
humans) (see (Reiss and Saftig 2009) for a review).  
ADAMs are mostly type I transmembrane glycoproteins with a conserved domain structure 
consisting of an N-terminal signal sequence, a prodomain, a metalloprotease domain, a 
disintegrin domain, an EGF domain, a transmembrane domain and a cytoplasmic tail. G 
protein-coupled receptors (GPCRs) together protein kinase C (PKC) and second messengers 
such as Ca2+ and reactive oxygen species (ROS) have been shown to activate ADAMs and 
transactivate the EGFR (Ohtsu, Dempsey et al. 2006) (Figure 3). 
 
 
Fig. 3: EGFR transactivation through pro-EGFR ligands shedding by ADAMs. G-protein 
coupled receptors (GPCRs) together with second messengers (Ca2+, PKC, UV-induced ROS) induce 
ADAM activation and thereby lead to shedding of EGFR ligand precursors that in turn activate EGFR. 
ADAM metalloproteases consist of a prodomain (PRO), a metalloprotease domain (MP), a disintegrin 
domain (DIS), a EGF-like domain (EGF), a transmembrane domain (TM) and a cytoplasmic tail (CT).  
Two ADAM members are critical for shedding of most EGFR ligands: ADAM10 and ADAM17. 
ADAM10 has been shown to be responsible for cleavage of EGF and BTC while ADAM17 is 
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involved in shedding of AREG, EPGN, EREG, HBEGF and TGFA (Sahin, Weskamp et al. 2004; 
Sahin and Blobel 2007).  
 
In human cancers, several ADAMs were reported to be overexpressed. Frequently, expression 
levels correlated with tumor progression (Rocks, Paulissen et al. 2008). This implicates a role 
of ADAMs in cancer progression. Consequently, ADAMs are currently tested in xenograft 
and preclinical models (Zhou, Peyton et al. 2006; Fridman, Caulder et al. 2007) as new targets 
for cancer therapy, showing encouraging results by inhibiting tumor cell growth when used in 
synergy with existing therapies. 
Still, the mechanisms of ADAM protease regulation are only partly resolved. To date, not 
much is known about the transcriptional regulation of ADAMs in the normal and pathological 
state and further investigations that could benefit cancer therapy are needed.    
 
4.9. EGFR oncogenic functions   
As Egfr controls critical aspects of cell proliferation, motility, differentiation and survival, it 
is not surprising that its deregulation is implicated in many oncogenesis processes (see 
(Mitsudomi and Yatabe 2010) for a review).  
Oncogenic Egfr deregulation can take place at multiple levels: autocrine activation, 
overexpression of the receptor, activating receptor mutations and defects in receptor 
internalization and degradation (see for a review (Normanno, De Luca et al. 2006)). 
Noteworthy, co-expression of different members of the EGFR family of tyrosine kinase 
receptors occurs in the majority of solid tumors (Singer, Hudelist et al. 2004). 
EGFR is often upregulated in human breast cancers, and the co-expression of TGFa and 
EGFR correlates with a poor overall prognosis (Umekita, Ohi et al. 2000). EGFR is expressed 
in 20 to 80% of non-small cell lung cancer (NSCLC) tumors (Fontanini 1998), with 
deregulation mostly being the result of amplifications and mutations. Also NSCLC tumors are 
positive for EGFR ligands including TGFA and AREG, which correlates with a poor patient 
prognosis (Hodkinson, Mackinnon et al. 2008). EGFR also plays a role in colon cancer, with 
metastatic colon cancer cells expressing five times more EGFR than the nonmetastatic cells 
and the receptor-ligand pair EGFR-TGFA being a characteristic feature of more advanced 
tumors (Sasaki, Nakamura et al. 2008). A mutation of the EGFR, EGFRvIII, is found in more 
than 50% of glioblastoma multiforme (GBM), the most common and aggressive type of 
primary brain tumor in humans. This mutation, responsible for constitutive activation of the 
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ERK pathway and impairment of internalization and degradation, is implicated in 
uncontrolled cell proliferation (Grandal, Zandi et al. 2007).  
Evidences are accumulating for a role for EGFR also in malignant melanoma. In recent 
publications, highly metastatic melanoma from patient biopsies and melanoma cell lines 
showed up-regulation of the EGFR (Fiori, Zhu et al. 2009) and human malignant melanoma 
cell growth was reduced in the presence of an EGFR inhibitor (Djerf, Trinks et al. 2009). 
EGFR was previously shown to be overexpressed in highly metastatic melanomas (Hoek, 
Schlegel et al. 2006) and EGFR activation has been demonstrated to play an important role in 
melanoma cell motility (Xie, Pallero et al. 1998; Gordon-Thomson, Jones et al. 2005). 
The EGF-family of peptide growth factors is also involved in the pathogenesis of human 
carcinomas, and in mammalian cells overexpression of EGFR is able to induce transformation 
only in presence of appropriate levels of ligands. EGFR ligands are overexpressed in 
numerous solid neoplasms and anticancer agents targeting the EGFR ligands are currently 
under development (Yotsumoto, Sanui et al. 2009).  
 
4.10. The Xiphophorus melanoma model   
In the field of cancer research, one of the oldest animal model systems is the platyfish 
Xiphophorus maculatus. Already in the 1920’s, Anders, Gordon, Kosswig and Haussler found 
that crossing the platyfish X.maculatus with the swordtail X.helleri gave rise to fish that 
spontaneously developed tumors resembling human malignant melanoma (Häussler 1928; 
Kosswig 1928; Gordon 1931). Pigment cells called macromelanophores that form 
characteristic black spots in the dorsal fin region (spotted dorsal or Sd phenotype) were found 
to be the source of these tumors. 
However, development of malignant melanoma only occurred in the hybrid progeny after 
backcrossing the F1 offspring of (X.maculatus x X.helleri) with X.helleri (Figure 4A). The 
dominantly acting pigment-cell specific Tu (for tumor, as this is the oncogenic locus) allele is 
harboured on X.maculatus sex chromosomes, but the presence of a regulator locus (R) on 
another chromosome in X.maculatus impairs Tu oncogenic effect. The swordtail X.hellerii 
lacks both Tu and R and its crossing with X.maculatus gives rise to a hybrid F1 with fish 
presenting only one allele for R and for Tu on their respective chromosome pairs. After 
backcross of these Tu/-; R/- F1 fish with X. hellerii, about 25% of the offspring harbour Tu in 
the absence of R on their set of chromosomes and these fish will develop highly invasive 
malignant melanoma (Figure 4A). Another 25% of the offspring harbours one copy of the R 
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and one copy of the Tu locus. These fish are genotypically and phenotypically similar to the 
F1 generation and display non-malignant hyperpigmentation and overproliferation of pigment 
cells. Interestingly, re-introduction of the R locus completely impairs melanoma formation in 
subsequent generations. Altogether, the Tu locus, in absence of the R locus, is responsible for 
the onset of tumor formation in pigment cells and this due to the molecular nature of the 
oncogene that is present at this locus. 
 
Fig. 4: Xiphophorus melanoma model. (A) Classical Gordon–Kosswig–Anders cross leading to 
generation of Xiphophorus fish spontaneously developing melanoma. Tu: tumor locus, R: tumor 
repressor locus. Fish that only harbour Tu in the absence of the R locus develop highly invasive 
melanoma. Adapted from (Meierjohann and Schartl 2006). (B) Chromosomal locations of 
xiphophorus egfra, egfrb (proto-oncogene), and xmrk (oncogene). The Tu locus harbouring xmrk is 
located close to important loci, like the macromelanophore-determining locus (Mdl), the red-yellow 
locus (RY) and the sex-determining region (SD). 
 
Positional cloning approaches allocated a gene encoding for a novel receptor tyrosine kinase 
to the Tu locus. This gene was found to be homologous to the human EGFR and was called 
xmrk for Xiphophorus melanoma receptor kinase (Wittbrodt, Adam et al. 1989). Importantly, 
X.maculatus mutants that lost the property to induce tumor formation when crossed to 
4. Introduction  23 
X.helleri showed disruption of the xmrk gene by a transposable element (Schartl, Hornung et 
al. 1999).  
In Xiphophorus, the above mentioned fish-specific genome duplication (FSGD) generated 
two orthologous copies for the egfr gene that have been maintained during evolution and that 
encode two different receptor proteins: Egfra and Egfrb. While egfra gene is located on an 
autosome on linkage group VI (Harless, Svensson et al. 1990), egfrb gene is located in the 
subtelomeric part of both sex chromosomes. In addition, a more recent intrachromosomal 
segmental duplication of a genomic region including egfrb led to the generation of the 
oncogenic xmrk (Gutbrod and Schartl 1999; Nanda, Volff et al. 2000; Froschauer, Korting et 
al. 2001). As xmrk originates from egfrb, the latter can be consideres as proto-oncogene. Xmrk 
is located about 1 Mb away from egfrb on the sex chromosomes, and therefore it linked to a 
new 5’ region that affects its transcription (Adam, Dimitrijevic et al. 1993; Volff, Korting et 
al. 2003) (Figure 4B).  
While classical epidermal growth factor receptors require the binding of one or several 
ligands in order to dimerize and become activated, Xmrk can form activated dimers without 
any ligand binding. Two activating mutations present on Xmrk extracellular part, namely 
G359R and C578S, have been shown to be responsible for conformational changes that allow 
spontaneous dimer formation (Gomez, Wellbrock et al. 2001) (Meierjohann, Mueller et al., 
2006).  
In Xiphophorus macromelanophores, overexpression of the oncogenic receptor tyrosine 
kinase Xmrk together with its constitutive activation massively activates tumorigenic 
signaling pathways. Three major signaling pathways have been identified downstream of 
activated Xmrk. They are very similar to Egfr signaling pathways already characterized in 
invertebrates and vertebrates (Nagaraj and Banerjee 2004; Sundaram 2006) (Burgess 2008) 
(Figure 5). Firstly, Xmrk activation and subsequent tyrosine residue phosphorylation on the 
intracellular carboxy-terminus of the receptor is generating docking sites for adaptor proteins 
with src homology (SH) domains. In the Xiphophorus malignant melanoma derived cell line 
PSM, Xmrk has been shown to be associated to the adaptor protein Grb2 directly and via the 
SH2 and SH3 domains of Shc. This association is followed by the induction of the 
Ras/Raf/MAPK signaling cascade responsible for cell proliferation, differentiation and tumor 
cell survival at ectopic sites (Wellbrock, Fischer et al. 1999; Wellbrock and Schartl 2000). 
Secondly, PI3-K (phosphatidylinositol 3-kinase) can also bind to Xmrk C-terminal 
phosphorylated tyrosine residues and be activated (Wellbrock, Fischer et al. 1999; Wellbrock 
and Schartl 2000). This binding is leading to the induction of anti-apoptotic signaling via the 
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downstream effector Akt. Thirdly, Xmrk-dependent activation of the STAT5 transcription 
factor also induces cell proliferation and resistance to apoptosis by interacting with the PI3K 
pathway (Baudler, Schartl et al. 1999; Wellbrock and Schartl 2000; Morcinek, Weisser et al. 
2002). Finally, the Src kinase Fyn has been shown to play an important role in Xmrk 
signaling, since this protein was found to interact into a ternary complex with Xmrk and PI3K 
and to activate PI3K when bound to Xmrk (Wellbrock and Schartl 2000). Fyn Src kinase 
when bound to the C-terminal part of Xmrk can also enhance MAPK pathway signaling by 
inhibition of the MAPK phosphatase 1 (MKP-1) (Wellbrock, Weisser et al. 2002). Moreover, 
Xmrk activation of Fyn that in turns interacts with activated focal adhesion kinase (FAK) 
induces migration of pigment cells from mouse and fish origins (Meierjohann, Wende et al. 
2006; Teutschbein, Schartl et al. 2009). 
 
 
  
Fig. 5: Molecular signaling pathways induced by Xmrk. Activation of STAT5 promotes 
proliferation event while STAT5 together with the PI3K pathway lead to anti-apoptotic event. Xmrk 
also induces the Ras-Raf-MAPK pathway which promotes proliferation event but also differentiation 
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by reducing the stability of the pigment specific MITF transcription factor. The tyrosine kinase Fyn is 
strongly activated by Xmrk and contributes both to proliferation and cell migration events. Adapted 
from (Meierjohann and Schartl 2006). 
 
4.11. Aim of the PhD thesis 
The Xmrk oncogene, responsible for the initiation and progression of highly aggressive 
metastatic melanoma in the Xiphophorus fish is encoding for a mutated version of the Egfr. 
The two mutations which are independently responsible for Xmrk constitutive activation and 
subsequent oncogenic signaling take place in the receptor extracellular domain. These 
mutations generate new intramolecular disulfide bridges that lead to permanent Xmrk 
dimerization (Meierjohann, Mueller et al. 2006). The first mutation, G336R, occurs in Xmrk 
subdomain 2 which contains the dimerization loop that usually responds to ligand binding. 
Consequently, G336R mutation-induced structure resembles the Egfr in its ligand-bound state 
but still does not affect the ligand-binding pocket built by subdomains 1 and 3. The second 
mutation, C555S, creates a new disulfide bridge between two subdomain 4 monomers, 
subdomain originally involved in receptor dimerization. Here again, the mutation does not 
affect the ligand-binding pocket. Therefore, it remains unclear if Xmrk despite its mutations is 
still able to bind Egfr ligands and moreover, it is not known if Xmrk is having an effect on 
Egfr ligands regulation. The aim of my PhD was to investigate the Egfr/Egfr ligands system 
with regard to Xmrk oncogenic signaling. 
Firstly, I started to investigate the Egfr/Egfr ligands system from an evolutionary point of 
view to better understand the situation in teleosts. I performed the phylogeny, synteny and 
expression analyses with a special interest for medakafish since we are currently working on a 
newly established transgenic mitf::xmrk medaka melanoma model for which I analyzed Xmrk 
signaling profiles in non-tumorigenic and tumorigenic tissues. 
Secondly, I analyzed the Egfr/Egfr ligands system in response to Xmrk oncogenic signal both 
in vitro and in vivo. I analyzed the expression of Egfr ligand and related sheddase genes in 
melanocytes carrying an inducible version of Xmrk and investigated the expression of 
Egfr/Egfr ligand system members in tumorigenic and non-tumorigenic tissues from adult 
transgenic mitf::xmrk medakafish. Finally I looked for Xiphophorus Egfrb functionality and 
for the possibility for Xmrk to interact with Egfr ligands.    
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5. Results and Discussion 
 
5.1. Evolution of the Egfr/Egfr ligand system in vertebrates 
As key regulator in normal cellular processes, the epidermal growth factor receptor (Egfr) is 
one of the most investigated receptor tyrosine kinases and is highly conserved from 
triploblastic invertebrates to vertebrates (Stein and Staros 2006; van Kesteren, Gagatek et al. 
2008). While one gene is encoding for the Egfr in the tetrapod lineage, the situation appears to 
be different in teleosts due to the teleost-specific genome duplication (TSGD) event that 
occurred about 350 million years ago in the actinopterygian stem lineage (Postlethwait, 
Amores et al. 2004; Meyer and Van de Peer 2005; Froschauer, Braasch et al. 2006). 
 
5.1.1. Potential subfunctionalization of teleost egfr 
Due to the lineage-specific genome duplication, teleosts often possess two copies of various 
genes. Whereas about 76 to 80% of duplicated genes become secondarily inactive and get lost 
during evolution (Jaillon, Aury et al. 2004; Woods, Wilson et al. 2005), about 15% of gene 
paralogs have been retained in duplicates over time. In this context, we found that duplicated 
genes for Egfr are present in the six teleost species investigated. They are termed egfra and 
egfrb (Figure 1A). On the contrary, the Egfr-related protein Erbb2, that shares a common 
ancestor gene with Egfr, has not been maintained in two copies during evolution (Figure 1A). 
 Noteworthy, Erbb2 is the sole Egfr-related family member without a ligand-binding site 
(Citri, Skaria et al. 2003). Egfr-related proteins ErbB3 and ErbB4, which are known to 
interact with their respective ligands in human and mouse, have also been retained in 
duplicates in medaka and three other teleost species (Froschauer, Braasch et al. 2006). 
The situation is different for Egfr ligand genes, where only one copy for each of the seven 
tetrapod Egfr ligands has been retained in known teleost genomes, with the only exception 
being zebrafish hbegf (Laisney, Braasch et al. 2010). 
Transcription analysis of all Egf receptors and ligands in adult medaka tissues, revealed 
differential expression of egfra and egfrb as well as their ligands in the tissues. Egfra was 
expressed mainly in spleen, kidney and skin together with hbegf, whereas egfrb was 
prominently expressed in gills, ovary and liver, together with tgfa, areg and ereg (Table 1).  
In his classic book, Evolution by Gene Duplication (1970) the geneticist and evolutionary 
biologist Susumu Ohno (February 1, 1928 – January 13, 2000) postulated that gene 
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duplication was the most important force in the evolution of higher organisms. In his theory, 
one of the duplicated genes when maintained in the genome can either loose its function and 
become inactive (“nonfunctionalization”) or acquire novel and beneficial functions 
(“neofunctionalization”). More recently, the theory of subfunctionalization stating that both 
gene duplicates acquire mutations resulting in the partition of the ancestral gene functions 
among the two duplicates emerged (Force, Lynch et al. 1999). Our expression pattern 
analyses suggest a scenario in which the two medaka Egfr copies may have different 
functions which justifies their maintenance in the medaka genome in line with the 
subfunctionalization process that is well-documented in teleosts (Force, Lynch et al. 1999; 
Postlethwait, Amores et al. 2004; Rastogi and Liberles 2005). In addition, according to their 
dissimilar expression patterns together with the receptors, Egfr ligands may also bind Egfra 
and Egfrb with different affinities.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Phylogeny of Egfr and Egfr ligand genes. 
The consensus tree is based on a 958 amino acid alignment using the maximum-likehood method (LG 
substitution model, 1,000 pseudosamples); bootstrap values for major nodes are given as percentages. 
Only bootstrap values above 50% are shown. The presumed third genome duplication event (3R) is 
shown and fish-specific gene duplicates are quoted as Egfra and Egfrb.  
Bootstrap values for Maximum Likehood and Neighbor Joining methods are shown. The tree was 
rooted on the branch leading to Egf sequences. Only bootstrap values above 50% are shown. 
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Table 1: co-expression of Egfr and Egfr ligand genes in medaka organs. 
 
5.1.2. Evolution of the vertebrate Egfr ligand gene family 
Phylogenetic analyses based on the alignment of the mature part of the Egfr ligands gave well 
supported orthology only for a subset of tetrapod and teleost ligand genes, namely Egf, Tgfa, 
Hbegf and Ereg. Therefore additional micro- and macro-synteny conservation analyses were 
performed to obtain further informations about the relationship between teleost Egfr ligands 
and their tetrapod counterparts. The genomic surroundings of the respective human, zebrafish, 
tetraodon and medaka Egfr ligand genes were analyzed with the Synteny Database (Catchen, 
Conery et al. 2009). Altogether, by combination of phylogenetic and synteny analyses, true 
orthologues for Egfr ligands were identified in all teleost genomes available. 
Synteny Database dot plots analyses of paralogous genes within the human genome 
demonstrated that the TGFA containing region on Hsa2, the EGF and ligand cluster (Epgn, 
Ereg, Areg and Btc) containing region on Hsa4, the HBEGF containing region on Hsa5 were 
highly synthenic to each other, as well as with a region of Hsa10 devoid of EGFR ligand gene 
(Figure 2).  
These results confirm previous studies proposing that parts of chromosomes Hsa2, Hsa4, 
Hsa5 and Hsa10 all derive from vertebrate protochromosome C. Protochromosome C was 
duplicated twice during the R1/R2 whole genome duplication giving rise to the gnathostome 
protochromosomes C0, C1, C2 and C3 (Nakatani, Takeda et al. 2007). 
Chromosomal locations of Egfr ligand genes in the chicken and teleost genomes are also 
compatible with being derived from vertebrate protochromosome C and its four gnathostome 
derivates, leading to the hypothesis that all Egfr ligand genes in the present vertebrate 
genomes can be traced back to a single pre-R1/R2 Egfr ligand gene. 
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Figure 2: Model of Egfr ligand gene family evolution in vertebrates. 
An ancestral gene on vertebrate protochromosome C was duplicated twice during the R1 and R2 
whole genome duplications. The gene on gnathostome protochromosome C0 was lost, while the gene 
on protochromosome C1 was duplicated intrachromosomally. One of the two descendent genes 
became Egf, the other one was duplicated in tandem giving rise to the ligand cluster. The 
protochromosome nomenclature follows ref. (Nakatani, Takeda et al. 2007). 
 
5.1.3. Evolutionary diversity of the receptor-ligand interface between tetrapods and 
teleosts 
The observed persistence of duplicated Egfr genes in teleosts, combined with the differential 
tissue expression of Egfr ligands in medaka (Laisney, Braasch et al. 2010) (Table 1), suggest 
differences in structure and function between the two fish Egfr copies. In addition, it is not 
clear how far teleost and tetrapod Egfrs are functionally conserved and to which extend a 
structure/function relationship is represented in the conservation of the primary structure, i.e. 
on the aminoacid level. Looking at the similarity values between tetrapod and teleost Egfr 
subdomains, we found that the extracellular domain, implicated in receptor dimerization and 
ligand-binding, is the least conserved part of the receptor.  
With the use of the bioinformatic ConSurf tool, we projected the amino acid alignment of 
tetrapod and teleost Egfr orthologues on a given 3D structure of the human EGFR/TGFA 
complex. The representation indicated that most of the Egfr residues building the ligand-
binding pocket are highly variable, thus they are not evolutionarily conserved between 
tetrapods and teleosts (Figure 3).  
A detailed examination of all known human Egfr amino acids that directly contact EGF or 
TGFA revealed that their medaka counterparts were mostly not conserved. More strikingly, 
some of them even showed a radical amino acid shift, i.e. a replacement by an amino acid 
with completely different physico-chemical properties. These data suggested a poor affinity of 
fish Egfr to mammalian EGFR ligands and the other way round. Therefore we tested the 
stimulation potential of human and medaka Egfr by human EGF, using melanocytes that 
expressed the respective receptor. Western blot analyses revealed that human EGF was able to 
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induce human EGFR phosphorylation, as well as phosphorylation of subsequent signaling 
pathway components. On the opposite, human EGF was not able to induce a response in cells 
expressing medaka Egfra. Further functional analyses demonstrated that the species-specific 
medaka Egfr ligands Egf, Areg and Hbegf were able to stimulate medaka Egfra (Figure 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: ConSurf evolutionary conservation analysis of the Egfr ligand binding pocket residues 
between tetrapods and teleosts. 
A) Overall strucure of extracellular subdomains I and III of Egfr in complex with Tgfa, 3 interface 
sites are outlined. Non-conserved residues are colored in turquoise whereas conserved residues are 
coloured in pink and maroon. Yellow color indicates amino acids for which data were not sufficient to 
calculate reliable conservation values (http://consurf.tau.ac.il/) (Landau, Mayrose et al. 2005). 
 
 
Altogether, these data speak against the use of heterologous ligands to stimulate fish Egf 
receptors. In most studies implying fish Egfr, heterologous growth factors from the EGF-
family are commonly used e.g. human or mouse EGF. 
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Figure 4: Western blot analysis of medaka Egfra activation by medaka Egfr ligands.  
Melan-a wildtype cells or melan-a Ola-egfra stimulated for 30 minutes at 37°C with overnight 
conditioned supernatant of 293-T cells expressing vector alone, medaka egf, medaka areg or medaka 
hbegf. P-Tyr: phospho-tyrosine antibody; P-Akt: phospho-Akt antibody; P-Erk1/2: phospho Erk1/2. 
The anti-P-Tyr antibody recognizes a band of the size of Egfra, thus indicating activated receptor. 
 
To explore potential paracrine regulatory mechanisms in zebrafish pituitary cells, use of 
heterologous human EGF was made but did not have any effect on the target genes 
investigated (Lin and Ge 2009). As zebrafish pituitary cells express Egfr (Lin and Ge 2009) 
and as EGF is having effects on pituitary cells in rat (Childs and Unabia 2001), it may be that 
use of heterelogous ligand in this case is inappropriate and would explain the fact that 
zebrafish pituitary cells do not react to human EGF.  
In goldfish, examination of prostaglandin synthesis showed lack of responsiveness for one of 
three classes of ovarian vitellogenic follicles expressing the Egfr when stimulated with mouse 
EGF (MacDougall and Van Der Kraak 1998). This lack of responsiveness can either be due to 
a change in the actions of EGF during ovarian follicular development in goldfish, but can also 
be the consequence of impaired cross-reactivity between fish Egfr and murine EGF that may 
occur with a different responsiveness when compared to the homologous goldfish Egfr-Egfr 
ligands system.     
5.2. The transgenic mitf::xmrk medaka in addition to Xiphophorus as animal model for 
melanoma 
Natural occurrence of melanoma has been described only in few species, namely human, 
opossums, dogs, cats, minipigs, horses and the platyfish Xiphophorus. Mice are protected 
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from natural development of melanoma since their epidermis is devoid of melanocytes, 
present in the hair follicle instead. 
With the spontaneous development of highly invasive and metastatic melanoma in certain 
hybrid genotypes, the Xiphophorus fish is one of the oldest animal models for human cancer. 
The overexpressed oncogene responsible for the onset of melanoma is encoding for a mutated 
version of the Egf receptor and was called Xmrk for Xiphophorus melanoma receptor kinase 
(for a review see (Meierjohann and Schartl 2006)). While melanoma is a multistep process in 
humans and mice, comprising oncogene activation, tumor-suppressor gene inactivation as 
well as epigenetic changes during tumor progression, oncogenic Xiphophorus Xmrk alone is 
able to trigger the onset of tumor formation as well as to sustain melanoma progression, at 
least in fish. By recruiting and activating multiple transcription factors, kinases and other 
adaptor proteins, Xmrk alone allows tumor initiation and progression by blocking cell 
differentiation, inducing cell proliferation and migration, and protecting from apoptosis 
events. While Xmrk downstream signaling events have been relatively well characterized, it is 
still unclear to what extent Xiphophorus the hybrid genetic background of Xiphophorus 
contributes to Xmrk induced tumorigenesis. Furthermore, Xiphophorus fish are live-bearing, 
thus impairing large-scale high-throughput analyses and transgenic approaches. The closely 
related fish species medaka (Oryzias latipes) is a widely used small-animal model system 
which offers several practical advantages when compared to Xiphophorus. Medaka fish 
produce externally developing transparent embryos, the full genome has been sequenced 
(Kasahara, Naruse et al. 2007), transgenic approaches are available (Thermes, Grabher et al. 
2002; Wittbrodt, Shima et al. 2002), and a number of in vitro systems have been established 
(Hong, Winkler et al. 1998; Hong, Liu et al. 2004). Therefore, we chose to examine xmrk-
dependent melanoma development in medaka. We generated stable transgenic medaka lines 
that express xmrk under the control of the pigment-cell specific mitf promoter. 
 
5.2.1. Melanoma phenotypes in the transgenic medaka 
The mitfa promoter from medaka was fused to the full-length cDNA of Xiphophorus xmrk 
oncogene and the resulting construct was injected into medaka embryos from the Carbio and 
albino (i-3) strains. Injected fish developed various pigmentation abnormalities due to the 
activity of the transgene. Embryos developing three-dimensional growth of darkly pigmented 
cells, also histologically diagnosed melanotic tumors, did not hatch and did not survive, while 
embryos developing large areas of hyperpigmentation or progressively growing pigment cell 
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tumors as juvenile or adult animal survived. Two types of tumors developed in the stable 
transgenic lines, namely pigment cell tumors of the red and yellow pigment-containing 
xanthophores and erythrophores (xanthoerythrophoromas or XE tumors) and melanoma, 
sometimes even on the same individual (Figure 5).  
Melanoma were detected at sites harbouring extracutaneous pigment cells (body musculature, 
internal organs, chorioidea of the eye, spinal cord, intestine), but also secondarily at sites 
devoid of extracutaneous pigment cells (liver). The latter had no connection to the main tumor 
mass and were therefore considered as metastases. A notable dosage effect was observed 
when comparing heterozygous and homozygous mitf::xmrk transgenic fish. Heterozygous fish 
developed f-nevi or cutaneous hyperpigmentation but also melanoma in the fins and the trunk 
at about 6-10 weeks of age and most of them developed hyperpigmentation of the 
xanthophore/erythrophore lineage, with presence of melanoma cells in between XE tumors 
(mixed tumors). Homozygous fish exhibited pigmentation disorders much earlier, and within 
2-6 weeks hyperpigmentated areas transformed into malignant tumors.  
 
Figure 5: Pigment cell tumors in mitf::xmrk transgenic medaka. 
A) Macroscopic and microscopic patterns of exophytic xanthoerythrophoroma. Upper image: 10-
weeks old female medaka (Carbio) with exophytically growing xanthoerythrophoroma. Lower image: 
Xanthoerythrophoroma growing in the dermal compartment and locally invading the underlying trunk 
musculature (arrows). Bar = 40µm. B) Macroscopic and microscopic patterns of invasive 
extracutaneous melanotic melanoma. Upper image: 4-weeks old juvenile medaka (Carbio) with 
melanotic tumor filling the abdomen and growing invasively into the musculature. Lower image: 
melanoma metastasis in the liver. Bar = 40µm. 
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5.2.2. Xmrk-induced signal transduction and gene expression in tumors 
Expression of the xmrk transgene in medaka tumors was high on transcriptional level and low 
to very high on protein level. Activation of Xmrk signal transducers that have been already 
characterized, like PI3K/AKT (Wellbrock, Fischer et al. 1999), MAPK/Erk (MEK) kinase 
and mitogen-activated protein kinase (MAPK) (Wellbrock, Weisser et al. 2002) was detected 
in transgenic medaka XE tumors and melanoma, but also, albeit at lower levels, in healthy 
fish skin. Interestingly, strong activation of signal transducer and activator of transcription 5 
(Stat5) correlated best with the level of xmrk expression in the tumors and reached the highest 
levels in the most malignant pigment cell type, the melanoma. Stat5 was already 
demonstrated to be of great importance for Xmrk-driven tumorigenesis events, inducing 
proliferation and antiapoptotic signaling of cultured cells (Wellbrock, Geissinger et al. 1998) 
(Baudler, Schartl et al. 1999) (Morcinek, Weisser et al. 2002). STAT5 is also implicated in 
cell survival and interferon resistance in human melanoma (Wellbrock, Weisser et al. 2005; 
Mirmohammadsadegh, Hassan et al. 2006) (Figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Western blot analysis of Xiphophorus hybrid and transgenic medaka tumors. 
Protein lysate of Carbio skin, xanthoerythrophoroma (XE tumors) and melanoma was analyzed using 
Western blot. Antibodies were directed against Xmrk (“Pepmrk), phosphotyrosine (P-Tyr), 
phosphorylated Mek, Mapk, Akt and Stat5. The upper Akt band is the specific one and is indicated by 
an arrow. Beta-actin is used as loading control. 
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The myc-family basic helix-loop-helix/leucine zipper microphtalmia-associated transcription 
factor (mitf) was found to be strongly upregulated along with xmrk expression in the more 
malignant medaka melanoma. The effect of MITF levels on human melanoma development is 
still under debate. It was reported that high MITF levels have an anti-proliferative effect on 
melanoma cells (Wellbrock and Marais 2005) whereas low levels of MITF were found in 
invasive melanoma (Hoek, Eichhoff et al. 2008) and are associated with bad prognosis and 
clinical disease progression (Zhuang, Lee et al. 2007). Still, the MITF gene was found to be 
amplified in 15-20% of metastatic melanomas (Garraway, Widlund et al. 2005) and 
expression of MITF in intermediate-thickness cutaneous melanoma is inversely correlated 
with overall survival (Salti, Manougian et al. 2000). Retention of MITF expression in most 
primary melanomas and non-pigmented tumors led to the common use of MITF as a 
prognostic marker in these malignancies (Chang and Folpe 2001). It is most likely that MITF 
plays both pro- and antiproliferative roles, depending in its level of expression and activity 
(Goding and Meyskens 2006). Noteworthy, at the protein level, MITF is the target of a range 
of modifications, e.g. phosphorylation and sumoylation, which control its expression or 
activity. The controversy of the MITF role in melanoma, anti-proliferative versus pro-
survival, is still not fully understood, and the strong expression of mitf in transgenic medaka 
malignant melanomas would rather support the hypothesis of a pro-tumorigenic and pro-
survival role in the transgenic mitf::xmrk medaka.  
Another factor that discriminated between the most malignant medaka tumors and the other 
tissue was the antiapoptotic protein Bcl-2, which was strongly upregulated only in melanoma. 
Interestingly, on transcriptional level bcl-2 was upregulated both in XE tumors and 
melanoma, suggesting that Bcl-2, like Mitf, are more strongly regulated by posttranscriptional 
than by transcriptional mechanisms in medaka tumors. In human, BCL-2 is a direct target 
gene of MITF (McGill, Horstmann et al. 2002). BCL-2 is one of the most important 
regulators of melanoma cell apoptosis (Soengas and Lowe 2003) and anti-sense suppression 
of BCL-2 or mutations in MITF lead to decreased melanoma cell survival and increased 
sensitivity to chemotherapy (Jansen, Schlagbauer-Wadl et al. 1998; Gautschi, Tschopp et al. 
2001; McGill, Horstmann et al. 2002). Consequently, BCL-2 is extensively investigated as 
therapeutic target in cancer and new BCL-2-targeting drugs currently undergo clinical trials 
(for a review see (Patel, Masood et al. 2009)).  
Another antiapoptotic gene, namely survivin1 was found to be transcriptionally upregulated in 
melanoma but not in uveal melanoma in transgenic mitf::xmrk medaka. Survivin1 is a 
member of the inhibitor of apoptosis (IAP) family and a human melanoma progression 
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marker (Chen, Gong et al. 2009). Its expression in human melanomas correlates with disease 
recurrence and poor survival (Piras, Murtas et al. 2007). Survivin expression was also found 
in human uveal melanoma, where it correlates with resistance to the pro-apoptotic tumor 
necrosis factor-related apoptosis inducing ligand (TRAIL) (Li, Niederkorn et al. 2005). 
Altogether, activation of signaling pathways and expression of genes known to be important 
in melanomagenesis or melanoma progression in human and/or Xiphophorus confirm that 
transgenic mitf::xmrk medaka is suitable as new fish melanoma model. This model could be 
especially useful to contribute to a better understanding of prosurvival signaling in pigment 
cell tumors, as upregulation of antiapoptotic Stat5, bcl-2 and survivin 1 both in XE tumors 
and melanoma was monitored. 
 
5.2.3. Genetic melanoma modifiers 
Both xanthoerythrophoromas and melanomas were observed in the transgenic medaka Carbio 
strain, which is a non-inbred line with mixed genetic background. To investigate Xmrk-
dependent oncogenicity according to genetic modifiers, the transgene was crossed into 
different medaka lines of defined genetic backgrounds. Strong differences were already 
observed after two generations. Fish from the CabR’ background developed almost 
exclusively xanthoerythrophoromas that invaded the underlying trunk musculature only at 
terminal stages. About 2-5% developed additionally nodular or invasive melanoma. On the 
contrary, fish from the HB32C genetic background developed mostly invasive extracutaneous 
melanoma, while xanthoerythrophoroma were extremely rare. The third group, fish from i-3 
albino background, showed hyperpigmentation of xanthophores in the skin that rarely evolved 
into tumors, and about 30% developed extracutaneous poorly pigmented melanoma from the 
intestine. Interestingly, about 40% of these fish also exhibited unilateral or bilateral eye 
melanoma. 
 
5.3. Xmrk melanoma model and Egfr ligands.  
Being a mutated version of the Egfr, it is conceivable that oncogenic Xmrk may interact with 
members of the Egfr ligand family. Moreover, receptor activation by autocrine loops is a 
common feature in receptor tyrosine kinase driven tumors. It is not known if Xmrk can bind 
Egfr ligand  but previous modeling studies of Xmrk extracellular domain structure could 
show that subdomains I and III, which build the interacting interface for the ligand, are not 
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affected by the two mutations that are responsible for constitutive Xmrk activation 
(Meierjohann, Mueller et al. 2006). This means that ligand binding to Xmrk, even in a pre-
dimerized state, may occur. It was already demonstrated that cell-surface EGFR dimers, either 
formed due to mutational activation (Moriki, Maruyama et al. 2001), or spontaneously formed 
by wildtype EGFR (Tao and Maruyama 2008), can bind EGF.  
 
5.3.1. Induction of EGFR ligands and related sheddases by human EGFR and Xmrk 
To investigate the role of human EGFR and Xmrk in the transcriptional regulation of EGFR 
ligands, we used immortalized mouse melanocytes cell line (melan-a) transgenic for human 
EGFR or an inducible version of Xmrk (called HERmrk; a chimera of the extracellular part of 
human EGFR and the intracellular part of Xmrk, thus activatable by human EGF). As melan-a 
cells do not express endogenous EGFR (Wellbrock, Weisser et al. 2002), EGF-dependent 
activation could only occur due to the respective transgene. Melan-a HER cells or melan-a 
HERmrk were stimulated with EGF and activation of the receptors and downstream signaling 
pathways was validated by Western blot analysis. Then, RNA expression of the seven Egfr 
ligands was monitored by quantitative realtime-PCR. Areg, Btc and Hbegf were strongly 
transcriptionally upregulated in melanocytes upon human EGFR activation (Figure 7). 
Simulation of HERmrk was even more potent and also led to induction of Ereg and Epgn in 
addition. However, Hbegf and Areg were the strongest upregulated ligand genes 2 hours post-
stimulation.  
The role of EGF family genes in melanoma onset and progression is attracting recently more 
and more attention. It is well-known that human melanoma cell lines frequently express high 
levels of TGFA (Marquardt and Todaro 1982; Richmond, Lawson et al. 1985), suggesting a 
possible autocrine EGFR/TGFA pathway. In the melan-a cells, we could not detect any 
transcriptional upregulation of Tgfa by either EGFR or HERmrk, but an autocrine receptor 
induction occurs through other ligands (see below).  
Of relevance in the context of the results exposed here, AREG and HB-EGF were found to be 
the two major EGFR ligands expressed in most human cancers cells. They are considered as 
suitable targets for cancer therapy (Yotsumoto, Yagi et al. 2008). In addition, Singh et al. 
reported UV induced activation of the EGFR by AREG in human cancer cells and observed 
overexpression of HB-EGF, AREG and BTC (and also TGFA) in different melanoma cell 
lines (Singh, Schneider et al. 2009).  
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Figure 7: Expression of mouse EGFR ligands in melan-a HERmrk cells upon addition of human 
EGF. 
Expression of Btc, Hbegf and Areg in melan-a HERmrk cells stimulated or not with human EGF (100 
ng/ml) for 2, 4 and 8 hours.  
 
In the mouse melanocyte system, the strong upregulation of Hb-egf and Areg both in 
activated HER and HERmrk melan-a cells was particularly striking. Both genes encode for 
the only EGFR ligands that possess an additional amino-terminal heparin-binding site in their 
precursor form. Heparin-binding sites enable binding of heparin sulphate proteoglycans 
(HSPGs) which are essential components of the cell surface and the extracellular matrix, 
allowing structural integrity and storage of growth factors and chemokines. HSPGs are 
overexpressed in many forms of cancer including melanoma (Ikuta, Nakatsura et al. 2005) 
and overexpression correlates with melanoma metastatic potential (Timar, Ladanyi et al. 
1992; O'Connell, Fiori et al. 2009). Still, their functions are largely unclear and still need to be 
investigated.  
To further elucidate the signaling pathways necessary for the strong upregulation of Hbegf 
and Areg in activated HERmrk melan-a cells, I investigated their transcriptional regulation 
upon addition of diverse inhibitors. We demonstrated that inhibition of HERmrk, MEK and 
SRC kinases could abolish Hbegf and Areg upregulation, whereas inhibition of the PI3K 
pathway had no effect (Laisney et al., in preparation). 
All Egfr ligand precursors are transmembrane proteins that are shedded by members of the “a 
disintegrin and metalloprotease” (ADAM) family to release the mature part of the ligand that 
interacts with its receptor. ADAM sheddases are therefore a major factor for posttranslational 
regulation of EGFR ligands and a rate limiting step in autocrine EGFR activation. They are 
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currently investigated as targets for the therapy of cancer and inflammatory diseases (see for a 
review (Tortorella, Malfait et al. 2009)). In mice, the two major ADAM proteins involved in 
EGFR ligand shedding are ADAM10 and ADAM17 (Sahin, Weskamp et al. 2004). In the 
HERmrk melanocyte model, we could observe that both ADAM10 and ADAM17 genes were 
slightly upregulated upon receptor activation, suggesting a role for ADAM metalloproteases 
in the EGFR ligand autocrine loop.   
 
5.3.2. Xmrk induces production of functional Egfr growth factors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: schematic representation of the conditioned HERmrk supernatants experiment. 
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After demonstrating regulation of Egfr/Egfr ligands on the transcriptional level in Hermrk 
transgenic cells, we wanted to elucidate whether Xmrk was able to induce secretion of active 
EGF family growth factors. We designed a “conditioned supernatant” experiment where 
supernatants from non-activated and activated HERmrk “donor” cells were collected and 
incubated together with unactivated HERmrk “receptor” cells (Figure 8). Only conditioned 
supernatant from stimulated Hermrk cells was able to trigger a signaling response in recipient 
HERmrk cells (Laisney et al., in preparation). Activation of HERmrk construct was 
monitored on protein level with Western blot analysis showing receptor, Akt and MAPK 
phosphorylations, but also on transcriptional level with realtime-PCR analyses displaying 
upregulation of known Hermrk target genes Osteopontin (Opn) and Egr1.   
 
5.3.3. Hyperactivation of Xmrk and related downstream signaling by autocrine 
stimulation.  
The Xmrk melanoma oncogene is a constitutively active mutated version of the Egfr, with at 
least two intermolecular disulfide bridges that allow disruption of the autoinhibitory tether 
and subsequent ligand-independent dimerization of the receptor (Gomez, Wellbrock et al. 
2001). Analysis of the structure of Xmrk extracellular domain (Meierjohann, Mueller et al. 
2006) revealed that these mutations do not affect the ligand binding pocket and do not 
obliterate the possibility for ligand binding to the pre-dimerized Xmrk. As we were using 
melan-a cells expressing whole Xiphophorus Xmrk protein, we decided to produce fish Egfr 
ligands in order to gain efficient receptor stimulation (Laisney, Braasch et al. 2010) (see 
chapter 5.1.3). Human Embryonic Kidney 293 cells (293-T) were transiently transfected with 
expression vectors for medaka Egf, Hbegf or Areg in order to gain conditioned supernatant 
containing the respective ligand. Then, wildtype melan-a cells or melan-a cells expressing 
Xiphophorus Egfrb (X-Egfrb) or Xiphophorus Xmrk were stimulated with these conditioned 
supernatants. Supernatants containing either medaka Egf or Hbegf were able to activate X-
Egfrb, as demonstrated by enhanced phosphorylation of Akt and MAPK on the Western blot 
analysis (Figure 8) and upregulation of known Egfr target genes p21, Mmp3 and Opn on 
realtime-PCR analyses. Interestingly, the already detectable Xmrk activation was further 
enhanced upon addition of conditioned supernatant with medaka Hbegf, demonstrated both on 
protein and transcriptional levels (Figure 9).  
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Figure 9: activation of Xiphophorus Xmrk by medaka Egfr ligands. 
Melan-a Xmrk was stimulated for one hour with supernatants from 293-T cells transiently transfected 
with vector alone, or with expression constructs for medaka Egf, Hb-egf or Areg. Antibodies were 
directed against Xmrk (Pepmrk), P-AKT  and P-MAPK. β-actin was used as loading control. Protein 
size is indicated in kDa. 
 
Activation mechanism of EGFR family proteins is complex. The extracellular part of the 
receptor is divided into four subdomains, I to IV. Subdomains I and III build the ligand 
binding interface, and in the closed conformation subdomains II and IV form a contact that 
keeps the receptor in an inactive tethered, auto-inhibited, conformation. Binding of ligand 
leads to a rotation between domains I and II, disrupting the interaction between domains II 
and IV, thus allowing an open conformation. In this state, the dimerization arm of domain II 
is exposed, enabling dimerization of two neighboring molecules (reviewed in (Riese, Gallo et 
al. 2007) (Ward, Lawrence et al. 2007)). Xmrk mutations in the extracellular domain create 
independently new disulfide bridges that disrupt the tethered conformation and additionally 
stabilize the close proximity of both intracellular kinase domains, thus allowing receptor 
activation without ligand binding. It is likely that Xmrk, in this pre-dimerized open 
conformation, is well accessible to ligand binding. In this case, ligand binding may lead to 
flexible rotation of the juxtamembrane region that would place intracellular tyrosine kinase 
domains in a position that will increase crossactivation and therefore enhance Xmrk signalling 
when compared to unbound receptor. This phenomenon has already been described for 
mutation-induced cell-surface localized EGFR dimers which were able to bind EGF (Moriki, 
Maruyama et al. 2001).  
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5.3.4. Regulation of the members of the autocrine Egfr loop in transgenic mitf::xmrk 
medaka  
To find out whether enhanced activation of oncogenic Xmrk may also take place in vivo, 
expression of Egfr ligands in xmrk-expressing medaka tumors was investigated.  
The expression of xmrk, egfra, egfrb, all egfr ligands, adam10 and adam17 was monitored in 
the two major medaka pigment cell tumors, the XE tumors and the melanoma. Gene 
expression levels in medaka Carbio healthy skin was taken as reference. A positive 
correlation was observed between expression of egfrb, areg and epgn in advanced stages of 
melanoma (Laisney et al., in preparation). An increased gene expression for egf, tgfa and btc 
was additionally monitored in the pigment cell tumors that occurred in fish also displaying 
metastatic melanoma. Adam10 and adam17 genes were also found to be slightly upregulated 
in the latter tumors. Altogether, we could provide many clues for the presence of an autocrine 
Egfr loop in the Xmrk-driven fish tumors. However, a discrepancy between the subset of 
upregulated Egfr ligand genes found in the Xmrk cell culture model (Areg, Btc and Hb-egf) 
and in the Xmrk transgenic fish tumors (Egf, Areg and Epgn) was observed. It is possible that 
this divergence may result from tumor niche effects (in vivo) or may reflect different states of 
oncogenic transformation.  
In regard to these data, Egfr ligands may possibly play a role in Xmrk-driven melanoma since 
overexpression of Egfr ligands in tumors from fish with melanoma metastases was observed. 
Still, it has to be elucidated how this autocrine Xmrk loop contributes to melanoma 
progression. It is also very likely that in Xmrk-driven tumors, overexpressed Egfr ligands can 
interact in the tumor microenvironment with native wildtype Egfrs present either on 
melanocyte cell surface, either with Egfr present on adjacent cells cell surface, e.g. epithelial 
cells of blood vessels, contributing in both cases to melanoma progression, tumor 
angiogenesis or vasculogenesis. In mice it has been demonstrated that not only melanoma but 
melanoma-derived endothelial cells show gain in EGFR expression when compared to normal 
endothelial cells. Moreover, melanoma-derived endothelial cells are responsive to EGF that 
induces endothelial cell proliferation (Amin, Hida et al. 2006). Additionally, as demonstrated 
in chapter 5.3.3., Egfr ligands may also interact with Xmrk to enhance its oncogenic signaling 
(Figure 10). 
The prominent role of EGFR ligands in cancer is already well established. For example, 
aggressive breast cancers co-over express EGFR and AR (LeJeune, Leek et al. 1993) and an 
EGFR-AR autocrine loop was identified in human breast cancer cells (Willmarth and Ethier 
2006). HBEGF has been showed to be overexpressed in ovarian cancer and proposed as 
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suitable target for cancer therapy (Miyamoto, Hirata et al. 2004). In lung cancer cells, the 
constitutive activation of EGFR is achieved by several mechanisms, including increased 
production of ligands (Fujimoto, Wislez et al. 2005). Anti-EGFR most clinically advanced 
targeted therapies are based on inhibition strategies including small-molecule inhibition of 
EGFR intracellular tyrosine kinase domain (gefitinib and erlotinib) and monoclonal antibody-
mediated blockade of EGFR extracellular ligand-binding domain (cetuximab) (Kataoka 
2009). However, solid tumors are often resistant to conventional treatment modalities, raising 
the need in developing novel therapeutic approaches. Lately, targeting of EGFR ligands has 
been proposed as promising for cancer therapy (Yotsumoto, Sanui et al. 2009) but is still in its 
early stages, with a phase I study of the use of a specific inhibitor of HBEGF for patients with 
recurrent ovarian cancer (Miyamoto, Fukami et al. 2009) and development of EGFR ligand-
sequestering drug (Cardo-Vila, Giordano et al. 2010).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Model for an autocrine activation of Egfr family members in Xmrk-driven 
melanoma. In tumor cells microenvironment, members from the Egfr family are activated by various 
mechanisms including mutation (Xmrk), overexpression and autocrine or paracrine production of Egf. 
Xmrk signaling induces Egfr ligands and respective sheddases expression through MAP-K and Src 
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pathways. Egfr ligands are secreted by the tumor cells either to stimulate Egfr family members located 
on the cell surface of tumor cells (autocrine mode of action) but may also stimulate members from the 
Egfr family located on adjacent cells (paracrine mode of action), like for exemple on melanoma-
derived endothelial cells from blood vessels, allowing vasculogenesis and angiogenesis events (Amin, 
Hida et al. 2006). 
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6. Conclusions 
Naturally occurring melanomagenesis in Xiphophorus fish is due to expression of the xmrk 
oncogene that encodes for a mutated version of the Egfr. Previous to this work, mechanisms 
of the constitutive activation of Xmrk and its cellular effects were thoroughly elucidated. Still 
it was unclear if Xmrk is able to bind Egfr ligands despite its permanent dimerization and also 
uncertain if Egfr ligands may play a role in Xmrk-driven melanoma.  
To better understand the situation of the Egfr/Egfr ligands system in teleost fish, I firstly 
investigated this system from an evolutionary point of view. Astonishingly, in all teleost 
species investigated, whereas Egfr gene has been kept in duplicates after the teleost-specific 
genome duplication, only one copy remains for each of all seven Egfr ligand. As I could show 
differential expression profiles for egfra and egfrb together with different subsets of ligands in 
adult medaka organs, we suggest a possible subfunctionalization of the Egfr in this fish, with 
partition of the ancestral gene functions between Egfra and Egfrb, which would explain the 
retention of the two gene copies during evolution. Also unexpected was the lack of 
conservation between tetrapod and teleost Egfr extracellular subdomains involved in ligand-
binding, implicating use of homologous, or closely-related species Egfr ligands as a 
prerequisite in experiment involving teleost fish Egfr, which is not the case actually. 
The next question was whether Xmrk can regulate the Egfr/Egfr ligands system. In 
melanocytes, I could demonstrate that Xmrk transcriptionally regulates Egfr ligand expression 
through MAPK and SRC pathways, suggesting an autocrine mode of activation. Taking 
benefit of our recently established transgenic mitf::xmrk medaka melanoma model, where I 
demonstrated Xmrk-induced signalling profiles are similar in Xiphophorus fish and in the 
newly established mitf::xmrk transgenic medaka fish were similar in non-tumorigenic and in 
tumorigenic tissues. These data together with histological and expression analyses confirm 
mitf::xmrk transgenic medaka as a suitable melanoma model in addition to Xiphophorus.   
I could show that a specific subset of Egfr ligands was higher upregulated in malignant 
tumors when compared to benign tumors. In addition, genes encoding for ADAM10 and 
ADAM17, which are sheddases critical for the release of soluble Egfr ligands, and one of the 
two medaka constitutional Egfr copies, Egfrb, were found to be upregulated in tumors from 
fish carrying metastases. These data strengthen the hypothesis of an autocrine loop in Xmrk-
driven melanoma, which may also involve a second Egf receptor, namely Egfrb. 
Importantly, medaka Hbegf was also able to enhance the already activated state of Xmrk. 
These results confirm that the Xiphophorus Egfrb/Xmrk/Egfr ligand system is functional and 
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that Xmrk can still binds its ligands, which enhance its activation and might contribute to its 
oncogenic potential. 
Self-suffiency in growth signals by autocrine growth factor production is one of the six 
hallmarks of cancer. In melanoma, oncogenic activation of mutated receptor tyrosine kinases 
(RTKs), like the fibroblast growth factor  receptor (FGFR), the cytokine receptor KIT, or the 
mesenchymal-epithelial transition factor (MET) are frequently associated to autocrine 
production of their specific ligands. Melanoma is usually resistant to chemotherapy and most 
of primary and metastatic melanomas express EGFR but respond badly to EGFR tyrosine 
kinase inhibitor alone. While most research has concentrated on the intracellular signal 
transduction, it would be of great interest to analyze into details melanoma cells secretome, a 
biological fluid that may be enriched with secreted and/or shed proteins. This approach should 
give better insight into the processes that lead to self-sustainability of the tumor and would 
help to define new targets for melanoma treatment. 
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Abstract  
Autocrine production of growth factors is a well-known phenomenon in receptor tyrosine 
kinase-related tumors. As a consequence, the tumor cells become largely independent of the 
stimulating effecs of neighboring cells, often leading to unrestricted proliferation. An 
aberrantly activated MAPK pathway, e.g. caused by BRAF- or RAS mutations, can lead to 
the production of several EGFR ligands which contributes to the tumorigenic potential of the 
oncogenically modified cell. Similarly, receptor tyrosine kinases can induce their own 
ligands, as described for EGFR, FGFR and PDGFR. 
In the Xiphophorus melanoma model, an oncogenic orthologue of the human EGF receptor 
drives the formation of aggressive melanoma. However, the fish harbours two further EGFR 
orthologues which can be expressed in the tumor or the tumor niche. To investigate whether 
autocrine activation of Egfr orthologues may contribute to tumor formation in this melanoma 
model, we investigated the transcriptional regulation of Egfr ligands by Xmrk. 
Using a cell culture model in which a chimeric and inducible form of Xmrk is expressed, we 
found a strong upregulation of secreted and active Hbegf and Areg after Xmrk stimulation. 
This was dependent on MAPK and SRC family kinase pathways. Accordingly, Xmrk-positive 
melanoma from mitf::xmrk transgenic medaka also displayed high levels of several Egfr 
ligands and, in addition, the two Egfr isoforms that are present in this species. We also 
investigated whether these ligands are capable of activating the fish receptors, and 
surprisingly found that not only the proto-oncogenic Egfr, but also the already dimerized 
Xmrk was further stimulated by fish-derived Egf and Hbegf.   
Altogether, we provide evidence for the presence of a functional Xmrk-dependent autocrine 
loop  in vitro and in vivo. This autocrine hyperactivation might be a general process which 
contributes to the oncogenic potential of those receptor tyrosine kinases that still maintain a 
functional ligand binding domain.   
 
Introduction 
Receptor tyrosine kinases of the epidermal growth factor receptor (EGFR) family are 
implicated in the development of many cancer types, e.g. breast cancer, non-small-cell lung 
cancer, colorectal cancer and glioblastoma (Salomon, Brandt et al. 1995; Blume-Jensen and 
Hunter 2001; Yarden and Sliwkowski 2001). Together with the breast cancer oncogene 
ERBB2, EGFR poses a promising target for medical intervention, and specific antibodies or 
small molecule inhibitors against EGFR are either already successfully used in the clinic 
   
(NSCLC, colorectal cancer (Govindan 2010; Ortega, Vigil et al. 2010)) or are in experimental 
stages, undergoing clinical trials (see for a review (Modjtahedi and Essapen 2009; Mitsudomi 
and Yatabe 2010)). Increased EGFR signalling in cancer cells can occur through several 
mechanisms. It can be due to increased receptor expression (often caused by gene 
amplification) activating EGFR mutations or autocrine loops mediated by enhanced ligand 
production (Miyamoto, Fukami et al. 2009).  
Activating EGFR mutations can be categorized into two main groups, characterized either by 
kinase domain mutations or by the deletion or mutation of extracellular parts. Non-small-cell 
lung carcinomas often display mutations of the first kind. In many glioblastomas, alterations 
of the second group are present, where the main part of the extracellular domain, including 
the ligand binding parts, is missing due to a deletion of exons 2-7 (Huang, Cavenee et al. 
2007; Laurent-Puig, Lievre et al. 2009). In addition, some cases of point mutations affecting 
extracellular Cys residues were also reported (Gomez, Wellbrock et al. 2001; Sihto, Puputti et 
al. 2005). These mutations lead to the disruption of intramolecular disulfide bridges and may 
facilitate the formation of intermolecular disulfide bridges. 
A role for the EGFR/EGFR ligand system is also emerging in initiation and progression of 
malignant melanoma, the most dangerous form of skin cancer. Here it was reported to be 
involved in many key melanomagenic processes including proliferation, cell migration, 
differentiation, survival and tissue homeostasis (Yarden and Sliwkowski 2001; Bardeesy, Kim 
et al. 2005; Djerf, Trinks et al. 2009; Singh, Schneider et al. 2009). 
Tumor development and progression can occur if cells escape from regulatory mechanisms. 
To be able to proliferate uncontrollably, cells must acquire growth autonomy. Usually, 
keratinocytes regulate melanocyte growth and behaviour by cell-cell adhesion molecules and 
growth factor production. Soluble growth factors can bind and activate receptors by paracrine, 
juxtacrine or autocrine modes of activation. Melanoma cells can escape control by 
keratinocytes using several mechanisms, including production of autocrine growth factors and 
enhanced expression of the respective receptors. It was previously described that melanoma 
cells are producing growth factors which activate the EGFR (Todaro, Fryling et al. 1980), 
such as transforming growth factor alpha (TGFA) and epidermal growth factor (EGF) 
(Krasagakis, Garbe et al. 1995). Correspondingly, EGFR expression or overexpression occurs 
in melanoma cells, thus contributing to their proliferation (de Wit, Moretti et al. 1992; Mattei, 
Colombo et al. 1994; Sparrow and Heenan 1999; Bardeesy, Kim et al. 2005; Akslen, 
Puntervoll et al. 2008; Djerf, Trinks et al. 2009). In addition, not only the melanoma tissue, 
   
but also the adjacent endothelial cells need EGFR signalling to allow tumor vasculature and 
growth (Amin, Hida et al. 2006).  
 
The Xiphophorus melanoma system provides an animal model where melanoma development 
is naturally induced by overexpression of a constitutively active version of the EGFR, called 
Xiphophorus melanoma receptor kinase (Xmrk) (Meierjohann, Schartl et al. 2004). The 
receptor is permanently dimerized due to the formation of intermolecular disulfide bridges 
(Gomez, Wellbrock et al. 2001; Winnemoeller, Wellbrock et al. 2005); however, structure 
predictions suggest that the ligand binding domain might still be accessible (Meierjohann, 
Mueller et al. 2006). Recently, a transgenic medaka melanoma model was produced by 
expressing the oncogene xmrk under the control of the pigment cell specific mitf promoter 
(Schartl, Wilde et al. 2009). Medaka is closely related to Xiphophorus but offers many 
additional advantages, like available transgenic technologies (Wittbrodt, Shima et al. 2002), 
in vitro systems (Hong, Winkler et al. 1998; Hong, Liu et al. 2004), and, importantly, a fully 
sequenced and well-annotated genome (Kasahara, Naruse et al. 2007). Moreover, all seven 
EGFR ligands have been characterized in medaka and their true orthology has been confirmed  
(Laisney, Braasch et al. 2010). 
Here, we investigate the role of the known EGFR ligands in an oncogenic EGFR-
driven tumor, using the Xmrk medaka melanoma model as well as melanocytes transgenic for 
an inducible version of Xmrk. We demonstrate the production of biologically active secreted 
ligands by Xmrk and human EGFR. Importantly, we observed an enhanced activation of 
already predimerized receptor by the produced autocrine factors. These results imply the 
involvement of autocrine factors in cancer progression, even if the receptor is already active 
due to oncogenic mutations that lead to a constitutively dimerized form. 
 
Results 
Activated human EGFR and Xmrk induce expression of EGFR ligands 
An oncogenic form of human EGFR, namely the truncated EGFRvIII, was previously 
reported to induce EGFR ligands such as HBEGF and TGFA in glioblastoma (Ramnarain, 
Park et al. 2006). Although these ligands cannot bind the truncated receptor, they can 
stimulate intact EGFR which is also present on glioblastoma cells.  
   
In order to check whether the oncogenic EGF receptor Xmrk also regulates transcription of 
EGFR ligands, we made use of a murine melanocyte model expressing the HERmrk chimera 
(melan-a HERmrk). This chimera consists of the extracellular part of human EGFR, fused to 
the intracellular part of Xiphophorus Xmrk. While Xmrk is constitutively active due to the 
existence of extracellular and intermolecular disulfide bridges, HERmrk signalling can be 
induced by adding EGF. Wildtype melan-a cells do not respond to EGF due to a lack of 
endogenous EGFR (Meierjohann, Wende et al. 2006; Leikam, Hufnagel et al. 2008). 
Expectedly, EGF treatment of melan-a HERmrk induced a strong time-dependent 
phosphorylation of the chimeric receptor and of its downstream targets AKT and MAPK 
(Figure S1A). Also, transcription of the known target gene Osteopontin, which is mediated by 
the MAPK pathway, was enhanced at all time points upon Xmrk activation (Figure S1B). The 
EGFR inhibitor AG1478 completely abolished all HERmrk signalling (Figure S1A and S1B). 
After this successful examination of HERmrk stimulation, we investigated the expression of 
all seven EGFR ligands by quantitative realtime-PCR analysis. All ligands except Tgfa and 
Egf showed transcriptional upregulation with maximal values 2 hours post stimulation (Figure 
1A). In particular, Hbegf and Areg displayed the highest upregulation (47.8 and 20.6 fold 
induction, respectively). We also investigated the effect of activating human full-length 
EGFR on transcriptional regulation of EGFR ligands in melanocytes. We made use of the 
melan-a cells transgenic for human EGFR (melan-a HER), stimulated them for one hour with 
human EGF and monitored expression of the seven EGFR ligands in both unstimulated and 
hEGF stimulated cells. A strong upregulation was observed for three of the seven ligands 
genes: Areg, Btc and Hbegf (Figure 1B). Importantly, the parental melan-a cell line, which 
does not express detectable amounts of endogenous EGFR, did not respond to EGF 
stimulation (data not shown and (Laisney, Braasch et al. 2010)). 
 
Activated Xmrk induces expression of Adam10 and Adam17  
Since “a disintegrin and a metalloprotease (ADAM) 10 and ADAM17 are the two major 
sheddases involved in membrane-anchored EGFR proligand release in mouse (Sahin, 
Weskamp et al. 2004), we investigated their regulation in melan-a HERmrk cells. Stimulation 
of melan-a HERmrk cells with human EGF resulted in a 2.6 fold increase of 
metalloproteinase Adam10 transcript and a 1.8 fold increase of Adam17 compared to the 
unstimulated control (Figure 1C).  
   
MEK and SRC kinases mediate the upregulation of autocrine factors 
As Hbegf and Amphiregulin displayed the highest upregulation upon HERmrk activation in 
melanocytes, we were interested in their upstream regulation. Thus, we applied EGFR 
inhibitor AG1478, MEK inhibitor U0126, SRC kinase inhibitor PP2 and PI3K inhibitor 
LY294002 in combination with hEGF. Inhibition of EGFR, MEK and SRC kinases, but not 
PI3K completely abolished the hEGF-mediated Hbegf and Areg upregulation (Figure 2). 
 
Metastatic melanomas express high levels of egfrb, egf, areg, epgn, adam10 and 
adam17  
Recently we described the generation of a new melanoma model, where stable expression of 
xmrk under the control of the mitf promoter drives pigment cell tumors in medaka (Schartl, 
Wilde et al. 2009). Here, two major types of pigment cell tumors are commonly observed. 
The first type is the exophytically growing xanthoerythrophoroma (derived from 
orange/yellow-coloured pigment cells that naturally occur in these fish), which has a low 
metastatic potential. The second tumor type is the melanoma which mostly derives from 
extracutaneous sites and is characterized by a high metastatic and invasive behaviour. 
Exophytic cutaneous tumors can either occur independently, or in combination with 
malignant and metastatic melanoma. In the latter situation, they are more advanced and 
contain nests of melanoma cells intermingled with the xanthoerythrophoroma (XE) cells 
(Schartl, Wilde et al. 2009). We compared exophytic tumour tissues from fish without 
melanoma with those from fish that additionaly displayed metastatic melanoma for their 
capacity to induce an autocrine EGFR loop (Figure 3A). The expression of the respective 
gene in skin tissue was used as reference. Expression of xmrk, the two egfr genes copy that 
occur in fish (egfra and egfrb), all Egfr ligands, adam10 as well as adam17 was monitored by 
quantitative realtime-PCR. Egfra and egfrb were expressed in all tumors, with a significant 
overexpression of egfrb in tumors that co-occured with metastatic melanoma (Figure 3B)  
Similarly, the EGFR ligands egf, tgfa, areg, btc and epgn were in most cases more strongly 
expressed in the tumors connected to metastatic melanoma when compared to those without 
melanocytic tumors (Figure 3C). However, in both tumor types the overall expression of tgfa 
was much lower than in skin tissue. The btc levels of the normal exophytic tumors were also 
lower than those observed in skin, but exophytic tumors linked to melanoma displayed levels 
comparable to levels in skin. No significant changes were noticed for ereg and hbegf 
Furthermore, adam10 and adam17 displayed a slight trend towards stronger expression in 
tumors linked to metastatic melanoma (Figure 3D), though this was not significant. 
   
Altogether, the data indicate a positive correlation between the expression of egfrb and the 
EGFR ligands areg and epgn and advanced stages of melanoma in the fish model. 
  
HERmrk stimulation leads to the production of functional EGFR growth factors 
So far, the transcriptional expression of EGFR ligands was demonstrated in HERmrk-
transgenic cells and in xmrk-transgenic medaka melanoma. To demonstrate the secretion of 
functional EGF family growth factors, we designed a “conditioned supernatant” experiment 
where the secreted factors from stimulated “donor” HERmrk melanocytes were used to 
stimulate a “receptor” cell population. The receptor cell population consisted of unstimulated 
HERmrk melanocytes. These cells only display activation of their HERmrk receptor when the 
conditioned supernatant of the hEGF-treated donor cells, which is transferred to the receptor 
cells, contains secreted EGFR ligands. Importantly, after stimulation with hEGF the donor 
cells were washed repeatedly to prevent the presence of hEGF in the conditioned supernatant. 
In addition, a short-time stimulation control was applied.  
The Western blot clearly demonstrated that only supernatant from activated HERmrk cells 
was able to trigger a signalling response (Figure 4A). Only here, phosphorylation of 
activation-associated sites in HERmrk, MAPK and AKT was visible, indicating that secreted 
and active growth factors were produced in the 8 h-conditioned supernatant. Furthermore, 
induction of the HERmrk target genes Osteopontin and Egr-1 was also exclusively observed 
in the receptor cells treated with supernatant from stimulated cells (Figure 4B and 4C).  
 
 
The oncogenic Xmrk induces an autocrine loop that enhances oncogenic signaling 
After having observed that HERmrk was able to induce an autocrine feedback loop, we 
wanted to find out whether the melanoma oncogene Xmrk itself was also responsive to its 
potential ligands. As the receptor is permanently dimerized due to the existence of at least two 
intermolecular disulfide bridges, an effect of ligand binding on receptor signaling was not 
previously expected.  In order to monitor stimulation of Xmrk that – as opposed to HERmrk – 
is no human-fish protein chimera but the entire Xiphophorus protein, we had to use fish 
EGFR ligands to gain specificity. It was shown previously that Xmrk and its proto-oncogene 
Egfrb do not bind mammalian EGF (Gomez, Volff et al. 2004) (own unpublished data). To 
produce fish EGFR ligands, we transiently transfected 293T cells with expression plasmids 
containing medaka egf, hbegf or areg (Laisney, Braasch et al. 2010), or with an empty 
expression plasmid as a control. The supernatant of these cells was then collected to stimulate 
   
wild-type melan-a cells (melan-a WT), or melan-a cells stably expressing either Xiphophorus 
Egfrb (melan-a X-Egfrb) as control, or Xmrk (melan-a Xmrk). As expected, melan-a WT 
cells treated with control or conditioned supernatant were not stimulated. (Figure 5A).  
However, medaka Egf and Hbegf containing supernatants clearly activated the proto-
oncogenic X-Egfrb, indicated by a strong phosphorylation of AKT and MAPK (Figure 5A). 
Additionally, the downstream genes p21 and Mmp3 displayed a robust induction when 
compared to controls (Figure 5C). Medaka Areg, however had no effect on Egfrb signaling, 
neither on protein nor on RNA level (Figure 5A and 5C). When we looked at the signaling 
capacity of constitutively activated Xmrk, we expectedly observed that melan-a Xmrk cells 
already showed receptor, AKT and MAPK activation with the control supernatant (Figure 
5A). Surprisingly, medaka Hbegf was able to further activate Xmrk, with considerable 
increase in AKT and MAPK phosphorylation. On RNA level, a slight but significant 
upregulation was observed for p21 and Mmp3 after stimulation of melan-a Xmrk cells with 
medaka Hbegf and Egf (Figure 5D). Altogether, these data indicate that although Xmrk is a 
predimerized oncogenic receptor, its activation is further enhanced by ligands which are 
produced in an autocrine manner by the receptor itself. 
 
Discussion 
Autocrine stimulation of receptor tyrosine kinases is a common feature of many tumors and 
contributes to their development. An oncogenic form of human EGFR, namely the truncated 
EGFRvIII, was previously reported to induce EGFR ligands such as HBEGF and TGFA in 
glioblastoma (Ramnarain, Park et al. 2006). Although these ligands cannot bind the truncated 
receptor, they can stimulate intact EGFR which is also present on glioblastoma cells.  
We report here that induction of EGFR ligands downstream of HERmrk is dependent on 
MAPK and SRC kinases. These observations are in concordance with published data, where 
SRC family kinases inhibitors hinder EGFR autocrine production of AREG (Kansra, Stoll et 
al. 2005) and HBEGF (Zhuang, Kinsey et al. 2008). Furthermore, the EGFR-RAS-RAF-
MEK-ERK axis is also known to upregulate EGFR ligands (Roberts and Der 2007), as shown 
in fibroblasts and human epithelial breast cells (McCarthy, Samuels et al. 1995) (Schulze, 
Lehmann et al. 2001). MAPK are responsible for phosphorylation and activation of JUN and 
FOS proteins that constitute the activator protein-1 (AP-1) transcription factor complex (Li, 
Ma et al. 2003). The transcriptional induction of Hbegf is directly mediated by AP-1 binding 
to their binding sites in the Hbegf promoter (Park, Adam et al. 1999; Kitamura, Miyazaki et 
   
al. 2001; Sakai, Tsukada et al. 2001; Li, Cheung et al. 2009). As SRC kinases such as FYN 
are involved in maintaining high levels of MAPK activation (Wellbrock, Weisser et al. 2002), 
it is possible that the observed blocking effect of the SRC kinase inhibitor is due the decrease 
of MAPK- and consequently AP-1 activity. 
Both human activated EGFR and HERmrk expressing melanocytes displayed highest 
expression levels for Hbegf and Areg among all seven EGFR ligands. Recently both ligands 
were demonstrated to be the most aberrantly expressed EGFR ligands in numerous human 
cancer cells, and even discussed as targets for cancer therapy (Yotsumoto, Yagi et al. 2008). 
Areg and Hbegf are the only EGFR ligands with an amino-terminal heparin-binding site, thus 
enabling binding of heparan sulphate proteoglycans (HSPGs) in addition to EGFR. HSPGs 
are essential components of both the cell surface, thus helping to provide structural integrity, 
and the extracellular matrix (ECM), being involved in storage of growth factors and 
chemokines. The mitogenic action of HBEGF has been shown to be increased when the 
ligand was associated with HSPG, through the formation of high-affinity ternary complexes 
stabilizing the receptor-ligand interaction (Higashiyama, Abraham et al. 1993). HSPGs are 
overexpressed in many forms of cancer, including melanoma (Ikuta, Nakatsura et al. 2005), 
but their role in melanoma in particular is scarcely documented. Former studies showed 
absolute or relative dominance of HSPGs over chondroitin sulphate proteoglycans (CSPGs) at 
the cell surface of metastatic melanoma tumor cells (Timar, Ladanyi et al. 1992). Recently, 
HSPGs increase in expression was demonstrated to be correlated with melanoma progression 
(O'Connell, Fiori et al. 2009), indicating a possible involvement/implication for HSPGs 
regarding melanoma metastatic potential.  
Interestingly, we observed that medaka Egf and Hbegf could further enhance the signalling 
downstream of predimerized Xmrk, as indicated by increased phosphorylation of AKT and 
ERK1/2 and the induction of downstream target genes. How can this be achieved? An 
explanation is probably found in the complex activation mechanism of EGFR family proteins. 
The extracellular domain (ECD) of EGFR is arranged into four domains. Domains I and III 
constitute the binding interface for the ligand. In the closed conformation, domains II and IV 
form a contact that keeps the receptor in a tethered conformation and therefore in an auto-
inhibited state. Binding of ligand leads to a rotation between domains I and II, thus disrupting 
the interaction between II and IV and allowing an open conformation. In this state, the 
dimerization arm of domain II is exposed, which enables the dimerization of two neighboring 
molecules that are both present in the open conformation (reviewed in (Riese, Gallo et al. 
2007; Ward, Lawrence et al. 2007)).  
   
According to the structural model for Xmrk, the mutations in the ECD lead to a free 
accessibility of cysteines 305 and 564. Both form a disulfide bridge with the corresponding 
residue of a neighboring receptor monomer, albeit not all molecules are predicted to contain 
both disulfide bridges (Meierjohann, Mueller et al. 2006). Importantly, Cys305 and Cys564 
are located in domains II and IV, respectively, with Cys564 being directly adjacent to those 
amino acid residues that are essential for the inhibitory interaction between domains II and IV 
(Mattoon, Klein et al. 2004; Dawson, Bu et al. 2007). This means that disulfide bridges at 
either Cys305 or at Cys564 disrupt the tethered conformation of the receptor and, in addition, 
stabilize the close proximity of both intracellular kinase domains. This explains the basal 
activity of Xmrk in absence of ligand. This model is supported by analogous observations by 
Moriki et al., who observed spontaneous dimerization of EGFR after introduction of cysteine 
residues into the extracellular juxtamembrane region of the receptor (Moriki, Maruyama et al. 
2001). Even in absence of ligand, the expression of some of these constructs was sufficient to 
cause cellular transformation of NIH3T3 cells, as indicated e.g. by soft agar growth (Moriki, 
Maruyama et al. 2001). A similar effect is observed with cells expressing a dimerizing EGFR 
mutant with insertions on both sides of the transmembrane region (Sorokin 1995). Still, even 
in the pre-dimerized state ligand binding and further receptor activation are possible. Several 
groups have observed that cell-surface localized EGFR dimers – either formed due to 
mutational activation (Moriki, Maruyama et al. 2001), or, to a smaller extent, spontaneously 
formed by wildtype EGFR (Tao and Maruyama 2008), can bind EGF. This induces a flexible 
rotation of the juxtamembrane region which is translated into the cytoplasmic domain and 
eventually leads to enhanced kinase activation. We propose a similar mechanism for Xmrk, 
which is arranged in a conformation where the autoinhibitory tether is disrupted by at least 
one of the two disulfide bridges. The open conformation that is stabilized by the dimer is well 
accessible to ligand, and ligand binding may lead to the described flexible rotation that places 
the intracellular kinase domains in a position that is optimal and allows a higher degree of 
crossactivation compared to the unbound receptor. 
In summary, we describe the induction of EGFR ligands by HERmrk/Xmrk in transformed 
pigment cells in-vitro as well as in a whole melanoma animal model. The ligands are able to 
enhance the activation state of the oncogene, and thereby contribute to the tumor phenotype. 
It is very likely that the same concept is valid in human tumors that contain activated 
oncogenes, such as c-KIT, EGFR or FGFR (Allerstorfer, Sonvilla et al. 2008; Hofmann, 
Kauczok-Vetter et al. 2009). 
   
 
Methods 
Cell culture  
Melan-a, melan-a HERmrk (Wittbrodt, Lammers et al. 1992), melan-a HER and melan-a X-
Egfrb cells (Gomez, Volff et al. 2004) were cultured as described earlier (Meierjohann, 
Wende et al. 2006). 
HEK 293T cells (human embryonic kidney fibroblasts with SV40 T-antigen) were grown in 
DMEM supplemented with 10% FCS, 1% glutamine and antibiotics.  
For the stimulation experiments, melan-a HERmrk and melan-a HER were cultivated in 
starving medium (Dulbecco's Modified Eagle's Medium with 1, 5 % dialysed foetal calf 
serum (Gibco/Invitrogen, Karlsruhe, Germany) for three days before EGF treatment. Where 
indicated, human EGF (100 ng/ml) (Tebu-bio, Offenbach, Germany) was added and melan-a 
HERmrk cells were collected after 2, 4 and 6 hours post-stimulation for melan-a Hermrk and 
2 hours post-stimulation for melan-a HER cells. Where indicated, EGFR inhibitor AG1478 
(10 µM), PI3K inhibitor LY294002 (10 µM), Fyn inhibitor PP2 (20 µM) or MEK inhibitor 
U0126 (10 µM) (all purchased from Calbiochem, Merck Chemicals Ltd., Darmstadt, 
Germany) were added to the starving medium one hour prior to the EGF stimulation. 
DNA transfection  
Melan-a cells were transfected with a Xiphophorus Egfrb expression plasmid (melan-a X-
egfrb) (Gomez, Volff et al. 2004) using Fugene transfection reagent (Roche) according to 
manufacturer’s recommendations. Expression constructs pCS2+-Ola-egf, pCS2+-Ola-areg 
and pCS2+-Ola-hbegf were transiently transfected into HEK 293T cells using the calcium-
phosphate method (Chen and Okayama 1987). 
 
Cell lysis and Western blotting 
Cells were trypsinized, rinsed twice with PBS and lyzed in 50 mmol/L HEPES (pH 7.5), 150 
mmol/L NaCl, 1.5 mmol/L MgCl2, 1 mmol/L EGTA, 10% glycerol, 1% Triton X-100, 10 
µg/mL aprotinin, 10 µg/mL leupeptin, 200 µmol/L Na3VO4, 1 mmol/L phenylmethylsulfonyl 
fluoride (PMSF), and 100 mmol/L NaF. 50 µg of protein lysate was separated by SDS-PAGE 
and analyzed by Western blotting onto nitrocellulose. Membranes were blocked for 60 
minutes with TBS [10 mmol/L Tris-HCl (pH 7.9) and 150 mmol/L NaCl], 0.1% Tween-20, 
and 5% bovine serum albumin (BSA) and were incubated overnight at 4°C with the first 
   
antibody. Monoclonal anti-phosphotyrosine antibody PTyr (PY20) was from BD Biosciences 
(San Jose, CA). Phospho-p44/42 MAPK (Thr202/Tyr204) antibody was purchased from Cell 
Signaling Technology (Danvers, MA). Rabbit polyclonal anti-phospho AKT was obtained 
from New England Biolabs (Ipswich, MA). Polyclonal anti-mrk recognising the C-terminal 
part of Xmrk was generated by Biogenes (Berlin, Germany).Anti-b-actin was purchased from 
Santa Cruz Biotechnology (Heidelberg, Germany). The secondary antibodies were conjugated 
with horseradish peroxidase and were directed against mouse (Pierce, Rockford, IL) or rabbit 
(Bio-Rad Laboratories, Redmond, WA). 
Fishes  
Fishes were kept under standard conditions in the aquarium facility of the Biozentrum at the 
University of Würzburg. The medaka (Oryzias latipes) strains tg(mitf::xmrk), genetic 
background Carbio (Schartl, Wilde et al. 2009) and wild-type Carbio were used in this study. 
RNA extraction, cDNA synthesis and realtime-PCR analysis 
RNA extraction from melan-a HERmrk cells and medaka tissues was done using Total RNA 
Isolation Reagent (ABgene, Epsom, UK) as recommended by the manufacturer.  
For all melanocyte cell lines and healthy medaka skin as well as mitf::xmrk medaka tumors, 
cDNA was prepared from total RNA cDNA was prepared using the RevertAid kit with 
random hexamer primers (Fermentas, Burlington, Canada). For analysis of gene expression, 
real-time PCR was done with primers designed using Primer3 software. primer sequences are 
available upon request. Each PCR was carried out in duplicate and was repeated 3 times 
independently in a 25 µl volume using a home-made SYBR green containing master mix for 4 
minutes at 95°C followed by 40 cycles of 95°C for 30 seconds and 60°C for 60 seconds in the 
iCycler IQ (Bio-Rad, Hercules, CA). All PCR products were checked by sequencing using the 
CEQ DTCS dye terminator cycle sequencing kit and run on a CEQ 2000XL DNA sequencing 
system (Beckmann Coulter, Krefeld, Germany).Values for each gene were normalized to 
expression levels of beta-actin (actin) using the 2-DDCT method (Livak and Schmittgen 
2001). Data are presented as mean ± standard deviation.  
 
Cloning of the expression constructs  
Full length cDNA encoding medaka egfra and medaka hbegf were PCR-amplified from 
medaka kidney cDNA, and medaka egf and areg were amplified from medaka brain cDNA. 
The respective primers were designed from the medaka genome database available on 
   
Ensembl Genome Browser (www.ensembl.org). To generate the different pCS2+ expression 
constructs, EcoRI and XbaI restriction sites were added to the 5’ and 3’ termini of medaka 
egf, EcoRI and XhoI were added to the 5’ and 3’ termini of medaka areg and ClaI and XbaI 
were added at the 5’ and 3’ termini of medaka hbegf, using PCR. The PCR products were 
digested with the respective enzymes and were ligated into the correspondingly digested 
pCS2+ vector. This gave rise to the vectors pCS2+-Ola-egf, pCS2+-Ola-areg and pCS2+-Ola-
hbegf. For the cloning of medaka egfra, Xba I and SnaBI restriction sites were added at the 5’ 
and 3’ termini, respectively. The PCR product was ligated into the XbaI and SnaBI digested 
pCS2+ expression vector to create the pCS2+-Ola-egfra construct. Gene accession numbers is 
given in supplementary table S1. 
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Figure legends 
 
Figure 1: Transcriptional regulation of EGFR ligands and their sheddases in response to 
HER and HERmrk stimulation (A-C). A: Expression of mouse EGFR ligands in melan-a 
HERmrk cells unstimulated or stimulated with human EGF (100 ng/ml) for 2, 4 and 8 hours. 
B: Expression of mouse EGFR ligands in melan-a HER cells unstimulated or stimulated with 
human EGF (100 ng/ml) for 2 hours. C: Expression of murine Adam10 and Adam17 in melan-
a HERmrk cells under the same conditions as in 1A. Results are average values of three 
independent quantitative realtime-PCR analyses normalized to β-actin expression level. 
 
Figure 2: Areg and Hbegf expression is regulated by SRC kinases and MAPK. 
   
Areg and Hbegf expression in melan-a HERmrk cells stimulated for 4 hours with human EGF 
in absence or presence of PI3K inhibitor (LY294002) (10 µM), SRC kinase inhibitor (PP2) 
(20 µM) or MEK inhibitor (U0126) (10 µM). Results are average values of three independent 
quantitative realtime-PCR analyses normalized to β-actin expression level. 
 
Figure 3: Expression of medaka EGF receptors, their ligands and sheddases in Xmrk-
driven tumors of different malignancy (exophytic tumors of fish without metastases and 
with (*) melanoma metastases) (A-D). A: mitf::xmrk transgenic medaka showing differences 
in tumor development. Left image: cutaneous exophytic xanthoerythrophoroma. Right image: 
extracutaneous invasive melanotic melanoma. B: Expression of medaka egfr-a and egfr-b. C: 
Expression of all Egfr ligands. D: Expression of adam10 and adam17. The expression was 
normalized to expression of the respective gene in medaka wild-type normal skin. 6 
individual fish were used for each group displayed by the box and whiskers representation, 
and each individual value is the average value of three independent quantitative realtime-PCR 
analyses normalized to ef1a1 expression. 
 
Figure 4: Recipient melan-a HERmrk cells show HERmrk activation only upon addition 
of conditioned supernatant from stimulated donor melan-a HERmrk cells (A-C). 
Recipient melan-a HERmrk cells were stimulated for 1 h with four different conditioned 
supernatants from donor melan-a HERmrk cells that were previously treated either for 5 
minutes or for 8 hours with or without recombinant human EGF. A: Western blot analysis. 
Antibodies were directed against phosphorylated tyrosine kinase (PTK), AKT (P-AKT) and 
MAPK (P-MAPK). β-actin was used as loading control. Protein size is indicated in kDa. B 
and C: Realtime analysis displaying the expression of murine Opn (B) and Egr1 (C) in 
recipient melan-a HERmrk cells incubated for 1 h with the conditioned supernatants from 
melan-a HERmrk donor cells. Results are average values of three independent quantitative 
realtime-PCR analyses normalized to β-actin. 
 
Figure 5: Egfrb and Xmrk are both stimulated by Egfr ligands (A-D). Melan-a wild type 
(WT), X-Egfrb or Xmrk were stimulated for one hour with supernatants from 293-T cells 
transiently transfected with vector alone or with expression constructs for medaka Egf, Hbegf 
or Areg. A: Western blot analysis. Antibodies were directed against Xmrk (Pepmrk), P-AKT 
and P-MAPK. β-actin was used as loading control. Protein size is indicated in kDa. B-D: 
Realtime PCR of Egfrb and Xmrk target genes. Expression of p21 (B), Mmp3 (C) and Opn 
   
(D) in melan-a wild type, melan-a X-Egfrb or melan-a Xmrk. Results are average value of 
three independent quantitative realtime-PCR analyses normalized to β-actin expression level. 
 
Supplementary figure 1:  
Activated melan-a Hermrk cells show activation of downstream pathways (A-B). A: 
phosphorylation of the chimeric Hermrk receptor, AKT and MAPK, as shown by Western 
blot analysis. Where indicated, melan-a HERmrk cells were stimulated with human EGF (100 
ng/ml) for 2, 4 or 8 hours in absence or presence of EGFR inhibitor AG1478 (10 µM). 
Antibodies were directed against Xmrk (Pepmrk), phosphorylated tyrosine kinase (PTK), 
AKT (P-AKT) and MAPK (P-MAPK). β-actin was used as loading control. Protein size is 
indicated in kDa. B: Expression of the target gene Opn in melan-a HERmrk cells stimulated 
with human EGF (100 ng/ml) for 2 hours, 4 hours or 8 hours in absence or presence of EGFR 
inhibitor AG1478 (10 µM). Results are average values of three independent quantitative 
realtime-PCR analyses normalized to β-actin expression level. 
 
 
 
   
 
 
 
   
 
   
 
 
   
 
   
 
   
 
 
 
  
